US20230272445A1 - Glycosylation of proteins - Google Patents
Glycosylation of proteins Download PDFInfo
- Publication number
- US20230272445A1 US20230272445A1 US18/056,126 US202218056126A US2023272445A1 US 20230272445 A1 US20230272445 A1 US 20230272445A1 US 202218056126 A US202218056126 A US 202218056126A US 2023272445 A1 US2023272445 A1 US 2023272445A1
- Authority
- US
- United States
- Prior art keywords
- mgat5
- st3gal3
- sppl3
- st3gal4
- st3gal6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 98
- 238000006206 glycosylation reaction Methods 0.000 title abstract description 11
- 230000013595 glycosylation Effects 0.000 title abstract description 10
- 102000004169 proteins and genes Human genes 0.000 title description 21
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 38
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 38
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 9
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 claims description 238
- 102100023501 Signal peptide peptidase-like 3 Human genes 0.000 claims description 236
- 101150086210 Mgat5 gene Proteins 0.000 claims description 235
- 101000828788 Homo sapiens Signal peptide peptidase-like 3 Proteins 0.000 claims description 233
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 claims description 232
- -1 SERPINAS Proteins 0.000 claims description 139
- 210000004027 cell Anatomy 0.000 claims description 122
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 claims description 43
- 102100035628 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 Human genes 0.000 claims description 32
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims description 29
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 claims description 27
- 102100029962 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Human genes 0.000 claims description 21
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 claims description 20
- 102100022977 Antithrombin-III Human genes 0.000 claims description 18
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 claims description 17
- 101000874526 Homo sapiens N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 Proteins 0.000 claims description 16
- 102100027107 Type 2 lactosamine alpha-2,3-sialyltransferase Human genes 0.000 claims description 16
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 claims description 14
- 108090000935 Antithrombin III Proteins 0.000 claims description 12
- 101000863898 Homo sapiens CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Proteins 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 101000836755 Homo sapiens Type 2 lactosamine alpha-2,3-sialyltransferase Proteins 0.000 claims description 11
- 102000008847 Serpin Human genes 0.000 claims description 10
- 108050000761 Serpin Proteins 0.000 claims description 10
- 229960005348 antithrombin iii Drugs 0.000 claims description 10
- 239000003001 serine protease inhibitor Substances 0.000 claims description 10
- 102000004506 Blood Proteins Human genes 0.000 claims description 9
- 108010017384 Blood Proteins Proteins 0.000 claims description 9
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims description 9
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 claims description 9
- 150000004676 glycans Chemical group 0.000 claims description 9
- 101000951392 Homo sapiens Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 claims description 8
- 108050007539 Plasma protease C1 inhibitor Proteins 0.000 claims description 8
- 102100030420 Serpin A9 Human genes 0.000 claims description 7
- 230000033581 fucosylation Effects 0.000 claims description 7
- 102000051631 human SERPINA1 Human genes 0.000 claims description 7
- 101000757319 Homo sapiens Antithrombin-III Proteins 0.000 claims description 6
- 102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 claims description 6
- 102100033299 Glia-derived nexin Human genes 0.000 claims description 5
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 claims description 5
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 claims description 5
- 101000711475 Homo sapiens Serpin B10 Proteins 0.000 claims description 5
- 101000868880 Homo sapiens Serpin B13 Proteins 0.000 claims description 5
- 101000836079 Homo sapiens Serpin B8 Proteins 0.000 claims description 5
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 claims description 5
- 102100023012 Kallistatin Human genes 0.000 claims description 5
- 102100030635 Leukocyte elastase inhibitor Human genes 0.000 claims description 5
- 102100037591 Neuroserpin Human genes 0.000 claims description 5
- 101150097162 SERPING1 gene Proteins 0.000 claims description 5
- 102100034012 Serpin B10 Human genes 0.000 claims description 5
- 102100032322 Serpin B13 Human genes 0.000 claims description 5
- 102100025512 Serpin B6 Human genes 0.000 claims description 5
- 102100025520 Serpin B8 Human genes 0.000 claims description 5
- 102100025517 Serpin B9 Human genes 0.000 claims description 5
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims description 4
- 102000004881 Angiotensinogen Human genes 0.000 claims description 4
- 108090001067 Angiotensinogen Proteins 0.000 claims description 4
- 102100032323 Corticosteroid-binding globulin Human genes 0.000 claims description 4
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims description 4
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 claims description 4
- 101000868967 Homo sapiens Corticosteroid-binding globulin Proteins 0.000 claims description 4
- 101001082432 Homo sapiens Heparin cofactor 2 Proteins 0.000 claims description 4
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 claims description 4
- 101000602167 Homo sapiens Neuroserpin Proteins 0.000 claims description 4
- 101000609261 Homo sapiens Plasminogen activator inhibitor 2 Proteins 0.000 claims description 4
- 101000823100 Homo sapiens Putative alpha-1-antitrypsin-related protein Proteins 0.000 claims description 4
- 101000642462 Homo sapiens Putative serpin A13 Proteins 0.000 claims description 4
- 101000642453 Homo sapiens Serpin A12 Proteins 0.000 claims description 4
- 101000711467 Homo sapiens Serpin B11 Proteins 0.000 claims description 4
- 101000868878 Homo sapiens Serpin B12 Proteins 0.000 claims description 4
- 101000836066 Homo sapiens Serpin B6 Proteins 0.000 claims description 4
- 101000836084 Homo sapiens Serpin B7 Proteins 0.000 claims description 4
- 101000836388 Homo sapiens Serpin E3 Proteins 0.000 claims description 4
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 claims description 4
- 101000711237 Homo sapiens Serpin I2 Proteins 0.000 claims description 4
- 101000837639 Homo sapiens Thyroxine-binding globulin Proteins 0.000 claims description 4
- 108090000144 Human Proteins Proteins 0.000 claims description 4
- 102000003839 Human Proteins Human genes 0.000 claims description 4
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 claims description 4
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 4
- 102100036394 Putative serpin A13 Human genes 0.000 claims description 4
- 102100036400 Serpin A12 Human genes 0.000 claims description 4
- 102100034019 Serpin B11 Human genes 0.000 claims description 4
- 102100032321 Serpin B12 Human genes 0.000 claims description 4
- 102100036383 Serpin B3 Human genes 0.000 claims description 4
- 102100025521 Serpin B7 Human genes 0.000 claims description 4
- 102100027290 Serpin E3 Human genes 0.000 claims description 4
- 102100027287 Serpin H1 Human genes 0.000 claims description 4
- 102100034076 Serpin I2 Human genes 0.000 claims description 4
- 102100028709 Thyroxine-binding globulin Human genes 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 102100035991 Alpha-2-antiplasmin Human genes 0.000 claims description 3
- 101000783712 Homo sapiens Alpha-2-antiplasmin Proteins 0.000 claims description 3
- 101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 claims description 3
- 101000964691 Homo sapiens Protein Z-dependent protease inhibitor Proteins 0.000 claims description 3
- 101000642456 Homo sapiens Serpin A11 Proteins 0.000 claims description 3
- 101000701876 Homo sapiens Serpin A9 Proteins 0.000 claims description 3
- 101000642478 Homo sapiens Serpin B3 Proteins 0.000 claims description 3
- 101000701902 Homo sapiens Serpin B4 Proteins 0.000 claims description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims description 3
- 102100040790 Protein Z-dependent protease inhibitor Human genes 0.000 claims description 3
- 102100022709 Putative alpha-1-antitrypsin-related protein Human genes 0.000 claims description 3
- 108010005173 SERPIN-B5 Proteins 0.000 claims description 3
- 102100030326 Serpin B4 Human genes 0.000 claims description 3
- 102100030333 Serpin B5 Human genes 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 238000003780 insertion Methods 0.000 abstract description 6
- 230000037431 insertion Effects 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 abstract description 5
- 101000888841 Homo sapiens Glutamine synthetase Proteins 0.000 description 220
- 102100039611 Glutamine synthetase Human genes 0.000 description 219
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 27
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 27
- 108091033409 CRISPR Proteins 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 19
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 18
- 101710148605 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 Proteins 0.000 description 17
- 102100026732 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- 102100037995 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B Human genes 0.000 description 13
- 125000005629 sialic acid group Chemical group 0.000 description 13
- 238000001890 transfection Methods 0.000 description 12
- 238000010354 CRISPR gene editing Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 230000002779 inactivation Effects 0.000 description 9
- 238000001155 isoelectric focusing Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 101000628808 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 102000016387 Pancreatic elastase Human genes 0.000 description 8
- 108010067372 Pancreatic elastase Proteins 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000003828 downregulation Effects 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 230000009450 sialylation Effects 0.000 description 8
- 101710083574 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 7
- 241000699802 Cricetulus griseus Species 0.000 description 7
- 101000951413 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B Proteins 0.000 description 7
- 102000004856 Lectins Human genes 0.000 description 7
- 108090001090 Lectins Proteins 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 239000002523 lectin Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 101710140595 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B Proteins 0.000 description 6
- 101710111748 Signal peptide peptidase-like 3 Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 102000005396 glutamine synthetase Human genes 0.000 description 6
- 108020002326 glutamine synthetase Proteins 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 101710146120 Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 5
- 101710140591 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 5
- 101710170638 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 description 5
- 101710136191 Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 description 5
- 101710136075 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 238000012365 batch cultivation Methods 0.000 description 5
- 108010057005 beta-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000012914 anti-clumping agent Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000012350 deep sequencing Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- BWBDAEIIXBEFSS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) n-[2-[2-(diethylamino)ethylcarbamoyl]quinolin-6-yl]carbamate Chemical compound C1=CC2=NC(C(=O)NCCN(CC)CC)=CC=C2C=C1NC(=O)ON1C(=O)CCC1=O BWBDAEIIXBEFSS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- 102100031939 Erythropoietin Human genes 0.000 description 3
- 108010027343 Glycoprotein 6-alpha-L-fucosyltransferase Proteins 0.000 description 3
- 108700023372 Glycosyltransferases Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010015197 N-acetyllactosaminide alpha-2,3-sialyltransferase Proteins 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- 102100024078 Plasma serine protease inhibitor Human genes 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010370 cell cloning Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 3
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 108030001772 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferases Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 101710083563 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 Proteins 0.000 description 2
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 101001053641 Homo sapiens Plasma serine protease inhibitor Proteins 0.000 description 2
- 102100030928 Lactosylceramide alpha-2,3-sialyltransferase Human genes 0.000 description 2
- 108030003357 Lactosylceramide alpha-2,3-sialyltransferases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010040630 N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 description 2
- 102000002255 Secretory Proteinase Inhibitory Proteins Human genes 0.000 description 2
- 102000003838 Sialyltransferases Human genes 0.000 description 2
- 108090000141 Sialyltransferases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150084304 St6gal1 gene Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 101710204134 Type 2 lactosamine alpha-2,3-sialyltransferase Proteins 0.000 description 2
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 2
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010021726 alpha-1,3-mannosylglycoprotein beta-1,4-N-acetylglucosaminyltransferase Proteins 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 108010064886 beta-D-galactoside alpha 2-6-sialyltransferase Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108010023726 cytoplasmic antiproteinase Proteins 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 108030001793 Alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferases Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101710171941 Beta-1,3-galactosyltransferase 7 Proteins 0.000 description 1
- 102100031500 Beta-1,4-glucuronyltransferase 1 Human genes 0.000 description 1
- 108030003360 Beta-galactoside alpha-(2,6)-sialyltransferases Proteins 0.000 description 1
- TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 1
- 102100027098 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Human genes 0.000 description 1
- 101710083568 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Proteins 0.000 description 1
- 102100031973 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 101000703728 Homo sapiens Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 Proteins 0.000 description 1
- 101000729794 Homo sapiens Beta-1,4-glucuronyltransferase 1 Proteins 0.000 description 1
- 101000836774 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Proteins 0.000 description 1
- 101000960626 Homo sapiens Mitochondrial inner membrane protease subunit 2 Proteins 0.000 description 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
- 101000874523 Homo sapiens UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 101710150707 Inositol monophosphatase 2 Proteins 0.000 description 1
- 101710126176 Insulin-like growth factor 2 mRNA-binding protein 2 Proteins 0.000 description 1
- 101710106133 Intramembrane protease 2 Proteins 0.000 description 1
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710091916 Leukocyte elastase inhibitor Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 1
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010001953 Protein C Inhibitor Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000006028 Sambucus nigra Species 0.000 description 1
- 235000003142 Sambucus nigra Nutrition 0.000 description 1
- 101000959880 Solanum tuberosum Aspartic protease inhibitor 4 Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 108010025592 aminoadipoyl-cysteinyl-allylglycine Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000012575 bio-layer interferometry Methods 0.000 description 1
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 229940088949 cinryze Drugs 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000018330 developmental and epileptic encephalopathy, 15 Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BTWUORFYKAZQHW-UHFFFAOYSA-L disodium;2-hydroxy-3-[4-[4-[(2-hydroxy-3-sulfonatopropyl)amino]-3-methylphenyl]-2-methylanilino]propane-1-sulfonate Chemical compound [Na+].[Na+].C1=C(NCC(O)CS([O-])(=O)=O)C(C)=CC(C=2C=C(C)C(NCC(O)CS([O-])(=O)=O)=CC=2)=C1 BTWUORFYKAZQHW-UHFFFAOYSA-L 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 102000044507 human SERPING1 Human genes 0.000 description 1
- 102000053359 human ST6GAL1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 150000008146 mannosides Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108010080874 neuroserpin Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040002068 peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activity proteins Proteins 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010017282 serpin B6 Proteins 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C12Y204/99001—Beta-galactoside alpha-2,6-sialyltransferase (2.4.99.1)
Definitions
- the present invention relates to the finding of methods to shift the glycosylation profile of recombinant produced serum glycoproteins to the predominant bi-antennary form found in human plasma. This is accomplished by providing a mammalian cell line according to the invention with a series of knock outs and/or knock in's that facilitate this shift.
- glycoproteins and in particular human serum proteins are produced for a range of applications.
- AAT Alpha-1-antitrypsin
- C1Inh Plasma protease C1 inhibitor
- ATIII Antithrombin-III
- Serpin B1 Monocyte neutrophil elastase inhibitor
- PAI1 Plasminogen activator inhibitor I
- Alpha-1-antitrypsin is used for treatment of people with AAT-deficiency. Such deficiency may result in lethal lung disease and liver disease. Over one million people have been estimated to be deficient of AAT globally. Currently, AAT is purified from human plasma.
- This treatment regimen is both expensive (USD 52,000 per year per patient), and not optimal with regards to safety, as possible pathogens present in plasma may not be efficiently cleared.
- AAT has also been produced in CHO and human cells with an aberrant glycoprofile.
- this mammalian host cell by specific modification of a mammalian host cell with the downregulation or inactivation of a series of genes in combination with the insertion of other specific gene(s), this mammalian host cell is made into a cell that will produce glycoproteins with a glycosylation profile that more resemble the glycosylation profile found for the same glycoproteins naturally in humans, such as in human plasma.
- the present invention relates to a recombinant mammalian cell line having a) one or more of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 inactivated and/or downregulated; and b) optionally a gene encoding Beta-galactoside alpha-2,6-sialyltransferase 1 inserted.
- the endogenous gene Mgat4A is inactivated and/or downregulated.
- the endogenous gene Mgat4B is inactivated and/or downregulated.
- the endogenous gene Mgat5 is inactivated and/or downregulated.
- the endogenous gene St3Gal3 is inactivated and/or downregulated.
- the endogenous gene St3Gal4 is inactivated and/or downregulated.
- the endogenous gene St3Gal6 is inactivated and/or downregulated.
- the endogenous gene SPPL3 inactivated and/or downregulated.
- the endogenous gene B3GNT2 is inactivated and/or downregulated.
- the endogenous gene GLUL is inactivated and/or downregulated.
- the endogenous gene FUT8 is inactivated and/or downregulated.
- two, three, four, five, six, seven, or all eight of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 are inactivated and/or downregulated.
- two, three, four, five, six, seven, eight, or all nine of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, B3GNT2, and FUT8 are inactivated and/or downregulated.
- two, three, four, five, six, seven, eight, or all nine of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, GLUL and FUT8 are inactivated and/or downregulated.
- two, three, four, five, six, seven, eight, nine, or all ten of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, B3GNT2, GLUL and FUT8 are inactivated and/or downregulated.
- two genes selected from Mgat4A and Mgat4B are selected from Mgat4A and Mgat4B;
- genes selected from Mgat4A, Mgat4B, Mgat5, and St3Gal3 are selected from Mgat4A, Mgat4B, Mgat5, and St3Gal3;
- Mgat4A, Mgat4B, Mgat5, St3Gal3, and St3Gal4 Mgat4A, Mgat4B, Mgat5, St3Gal3, and St3Gal6; Mgat4A, Mgat4B, Mgat5, St3Gal3, and SPPL3; Mgat4A, Mgat4B, Mgat5, St3Gal3, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal4, and St3Gal6; Mgat4A, Mgat4B, Mgat5, St3Gal4, and SPPL3; Mgat4A, Mgat4B, Mgat5, St3Gal4, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal6, and SPPL3; Mgat4A, Mgat4B, Mgat5, St3Gal6, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal6, and FUT8; Mgat4A, Mgat4B, Mgat5, SPPL3, and FUT
- GLUL, Mgat4B, Mgat5, St3Gal3, and St3Gal4 GLUL, Mgat4B, Mgat5, St3Gal3, and St3Gal6;
- Mgat5 St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4B, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4B, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4B, Mgat5, St3Gal3, St3Gal6, SPPL3, and FUT8; Mgat4B, Mgat5, St3Gal3, St3Gal6, SPPL3, and FUT8; Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, FUT8; Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3; Mgat4A, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4A, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4A, Mgat5, St3Gal4, St
- Mgat4A Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, and SPPL3: Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, and FUT8;
- Beta-galactoside alpha-2,6-sialyltransferase 1 is inserted.
- the present invention relates to a method for the production of a recombinant protein of interest, the method comprising the steps of: a) culturing a population of recombinant mammalian cells according to any one of claims 4 - 8 in a suitable cell culture medium; and b) harvesting said human protein of interest from the cell culture or cell culture medium.
- the protein of interest is produced with a glycan structure similar or identical to the glycan profile of said glycoprotein of interest found in human plasma.
- the present invention relates to a recombinant human glycoprotein of interest produced according to the method of the invention.
- FIG. 1 Illustration of glycosylation profile with a fully sialylated bi-antennary structure without core fucosylation as found e.g. in human AAT from various sources, such as plasma-purified AAT.
- FIG. 2 Comparison of the glycoprofile of plasma-purified AAT and CHO-produced AAT.
- Wild-type CHO-produced AAT contains many different structures, with a core-fucosylated and partially to fully sialylated bi-antennary structure as the most dominant species, while plasma-purified contains almost exclusively a non-core-fucosylated fully sialylated bi-antennary glycostructure.
- CHO-derived sialic acids are linked by ⁇ 2-3 linkages, while plasma sialic acids are linked by ⁇ 2-6 linkages.
- FIG. 3 Glycoprofile of human AAT derived from the engineered cell lines described here. The described gene disruptions and gene insertion results in a non-core-fucosylated fully sialylated bi-antennary glycostructure with ⁇ 2-6 linked sialic acids as the predominant species.
- FIG. 4 Isoelectric focusing gel of AAT derived from plasma (lane 1 and 2), the glycoengineered cell lines described here (lane 3 and 4), and wild-type CHO (lane 5 and 6). Migration patterns of plasma- and glycoengineered CHO-derived are identical.
- FIG. 5 Elastase inhibition assay probing the activity of
- FIG. 6 St6Gal1 vector map
- FIG. 7 SerpinA vector map
- FIG. 8 SerpinG vector map
- FIG. 9 SerpinC1 vector map
- FIG. 10 Combined St6Gal1/SerpinA vector map
- FIG. 11 Combined St6Gal1/SerpinG vector map
- FIG. 12 Growth and N-glycan structures from CHO-S WT and 10 ⁇ KO cell lines.
- A Viable cell density and viability of batch cultures of CHO-S WT and two clonal cell lines with functional knockout of eight glycosyltransferases as well as GS and SPPL3. Error bars indicate the standard deviation of triplicates.
- B N-glycan analysis of total secreted proteins from CHO-S WT and the 10 ⁇ KO clones A and B.
- Elution time is indicated on the x-axis and y-axis represents signal intensity normalized to highest peak (C) Proportion of non-fucosylated, biantennary N-glycans with terminal galactose (A2G2) in total secreted proteins from CHO-S WT and 10 ⁇ KO clone A and B.
- C Proportion of non-fucosylated, biantennary N-glycans with terminal galactose (A2G2) in total secreted proteins from CHO-S WT and 10 ⁇ KO clone A and B.
- FIG. 13 FITC-SNA lectin staining of selected poly- and monoclonal cell lines.
- A Fluorescent images of CHO-S WT and A1-1 cell line. Cells were stained for alpha-2,6-sialic acid linkage with FITC-SNA (green) and for nuclei with Hoechst (blue). The bottom right corner bar displays a length of 500 ⁇ m
- B Comparison of FITC-SNA positive cells. FITC-SNA lectin staining of CHO-S WT, two 50 ⁇ M MSX polyclonal cell lines and four selected clones. Bars indicate the proportion of cells with positive FITC signal due to SNA lectin binding on alpha-2,6-linked sialic acids on the cell surface. Error bars represent standard deviation of three individual measurements per sample.
- FIG. 14 Growth profiles, product titers and specific productivities of selected producing and non-producing clones.
- A Viable cell densities and cell viabilities of CHO-S WT, 10 ⁇ KO B the rhA1AT-(A1-1 and A1-2) and rhCiINH- C1-1 and C1-2) producing clonal cell lines measured in batch cultures. Error bars indicate range of duplicate parallel cultures.
- B rhA1AT and rhC1INH titer in supernatants during the batch culture experiment. Error bars indicate standard deviation of three individual measurements from two shake flasks per clone.
- FIG. 15 Characterization of purified rhAlAT and rhC1INH.
- A SDS-PAGE gel analysis of commercially available Cinryze (pIC1INH) and Prolastin-C (plA1AT) as well as rhA1AT and rhC1INH purified from polyclonal CHO-S WT or from monoclonal cell lines derived from 10 ⁇ KO B. Removal of N-glycans by PNGaseF was performed where indicated. PNGaseF migrating as a ⁇ 40 kDa band is indicated with an asterisk and impurities of pIC1INH are indicated with arrows.
- B IEF gel analysis of same proteins as described for panel A.
- N-glycan structures annotated in clones A1-1 and C1-1, respectively, as well as A2G2S2 proportions of purified rhAlAT and rhC1INH compared to pIAlAT and pIC1INH.
- D Left panel: In vitro assay measuring the inhibition of elastase activity at different concentrations of pIAlAT and rhA1AT purified from clones A1-1 and A1-2. Error bars indicate range of duplicate measurements. Maximum proteolytic activity of porcine elastase was set to 100%.
- FIG. 16 N-glycan profiles, Overlay of CHO-S WT (dotted line) and Sppl3 KO (solid line) cell lines producing EPO and C1inh respectively. The effect of Sppl3 can be seen as a shift to larger N-glycans.
- FIG. 17 is a Table reciting nucleotide sequences for overexpression vectors referenced in Example 4.
- FIGS. 1 and 2 Glyco-analysis of human AAT from various sources revealed that plasma-purified AAT is glycosylated with a fully sialylated bi-antennary structure without core fucosylation.
- FIGS. 1 and 2 Glyco-analysis of human AAT from various sources revealed that plasma-purified AAT is glycosylated with a fully sialylated bi-antennary structure without core fucosylation.
- CHO-produced AAT contains many different structures with a partially and fully sialylated bi-antennary structure with core fucosylation as the most dominant species ( FIG. 2 ).
- the inventors of the present invention have found that a shift of the glycosylation profile of recombinant produced serum glycoproteins towards the predominant bi-antennary form found in human plasma, may be accomplished by knocking out or in any other way downregulating a selected a set of glycosylating enzymes. This will result in a 6, 7, 8, 9, 10 or 8-9 double knock out clone in which, glycoproteins, such as human serum proteins, such as human AAT are expressed.
- glycoproteins such as human serum proteins, such as human AAT are expressed.
- a host cell with these modifications may then be modified by insertion of a gene expressing an exogenous human glycoprotein of interest, such as a therapeutic human protein, such as a human serum protein, such as Plasma protease C1 inhibitor (C1Inh), Antithrombin-III (ATIII) or Human alpha-1-antitrypsin (AAT).
- a gene expressing an exogenous human glycoprotein of interest such as a therapeutic human protein, such as a human serum protein, such as Plasma protease C1 inhibitor (C1Inh), Antithrombin-III (ATIII) or Human alpha-1-antitrypsin (AAT).
- C1Inh Plasma protease C1 inhibitor
- ATIII Antithrombin-III
- AAT Human alpha-1-antitrypsin
- the mammalian cells used according to the present inventions is selected from the group consisting of a Chinese Hamster Ovarian (CHO) cells, such as CHO-K1; Baby Hamster Kidney (BHK) cell; COS cell; HEK293; NSO; SP2/0; YB2/0; HUVEC; HKB; PER-C6; or derivatives of any of these cells.
- CHO Chinese Hamster Ovarian
- the cell line according to the present invention is modified to express a gene expressing an exogenous human glycoprotein of interest, such as a human serum protein selected from any one human serpin of table 1:
- SERPINA1 Antitrypsin Alpha-1-antitrypsin or ⁇ 1-antitrypsin SERPINA2 Antitrypsin-related protein SERPINA3 Antichymotrypsin SERPINA4 Kallistatin (PI4) SERPINA5 Protein C inhibitor (PAI-3) SERPINA6 Corticosteroid-binding globulin SERPINA7 Thyroxine-binding globulin SERPINA8 Angiotensinogen SERPINA9 Centerin SERPINA10 Protein Z-dependent proteinase inhibitor SERPINA11 XP_170754.3 SERPINA12 Vaspin SERPINA13 XM_370772 SERPINB1 Monocyte neutrophil elastase inhibitor SERPINB2 Plasminogen activator inhibitor-2 (PAI2) SERPINB3 Squamous cell carcinoma antigen-1 SERPINB4 Squamous cell carcinoma antigen-2 SERPINB5 Maspin SERPINB6 Proteinase inhibitor-6 (PI6)
- the present inventors aimed to produce rhA1AT and rhC1INH in CHO-S with N-glycan profiles similar to pIAlAT and pIC1INH.
- the heterogeneous N-glycan profile of CHO-S WT cells was changed to more homogeneous profiles in bespoke cell lines with predominant A2G2 N-glycan structures. Disrupting nine N-glycosylation-related genes increased the A2G2 proportion on total secreted protein from 3.5% in CHO-S WT-derived cells to ⁇ 80% in 10 ⁇ KO cell lines.
- rhAlAT and rhC1INH produced in the 10 ⁇ KO cell lines described herein are not only exceeding sialylation levels of pIAlAT and pIC1INH but also reveal human-like alpha-2,6-sialylation instead of alpha-2,3-sialylation.
- the increased sialylation of rhAlAT had no impact on in vitro activity.
- the present inventors describes a strategy to successfully engineer the heterogeneous N-glycosylation profile of in particular CHO-S WT cells towards the specific A2G2S2 N-glycan structure with the purpose of producing serpins, such as rhA1AT and rhC1INH with N-glycan profiles similar to human plasma-derived products.
- the present invention shows the promise and potential of replacing cost-intensive and possibly unsafe plasma-derived augmentation therapy for AATD and C1INH-HAE patients by CHO- produced rhAlAT and rhC1INH.
- This strategy is in compliance with the Medical and Scientific Advisory Council (MASAC) recommendation of replacing plasma-derived products with recombinant products for treatment of diseases.
- MASAC Medical and Scientific Advisory Council
- Alpha-1-antitrypsin refers to the protein identified as UniProtKB-P01009 (A1AT_HUMAN).
- Plasma protease Cl inhibitor refers to the protein identified as UniProtKB-P05155 (IC1_HUMAN)
- Antithrombin-III refers to the protein identified as UniProtKB-P01008 (ANT3_HUMAN)
- inactivated and/or downregulated refers to a modification of a mammalian host cell, wherein some specific genes are either knocked out, downregulated, or completely or partially inactivated in any other way, such as by miRNA post translational silencing. Preferably this inactivation is a complete inactivation with no measurable sign of expression of this particular gene being inactivated. Suitable techniques to silence/knockout are very well described in the art and known to the person skilled in the art, e.g. as described in WO2015092737. In one specific embodiment, “inactivated and/or downregulated” refers to a gene knockout of the relevant gene.
- MAT4A refers to the gene encoding Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isozyme A. This gene may also be referred to as
- MAT4B refers to the gene encoding Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isozyme B. This gene may also be referred to as
- MGATS refers to the gene encoding Mannosyl (Alpha-1,6-)-Glycoprotein Beta-1,6-N-Acetyl-Glucosaminyltransferase. This gene may also be referred to as
- ST3GAL3 refers to the gene encoding ST3 Beta-Galactoside Alpha-2,3-Sialyltransferase 3. This gene may also be referred to as ST3Gal III;
- ST3GAL4 refers to the gene encoding ST3 Beta-Galactoside Alpha-2,3-Sialyltransferase 4. This gene may also be referred to as Sialyltransferase 4C (Beta-Galactosidase Alpha-2,3-Sialytransferase);
- ST3GAL6 refers to the gene encoding ST3 Beta-Galactoside Alpha-10 2,3-Sialyltransferase 6. This gene may also be referred to as CMP-NeuAc:Beta-Galactoside Alpha-2,3-Sialyltransferase VI;
- B3GNT2 refers to the gene encoding UDP-GlcNAc:BetaGal Beta-1,3-N-Acetylglucosaminyltransferase 2. This gene may also be referred to as UDP-GIcNAc:BetaGal Beta-1,3-N-Acetylglucosaminyltransferase;
- GLUL refers to the gene encoding glutamate-ammonia ligase also referred to as:
- SPPL3 refers to the gene encoding Signal Peptide Peptidase Like 3. This gene may also be referred to as
- FUT8 refers to the gene encoding Fucosyltransferase 8. This gene may also be referred to as
- ST6Gal1 refers to the gene encoding ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1. This gene may also be referred to as ST6Gal I;
- the present invention relates to a recombinant mammalian cell line having a) one or more of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 inactivated and/or downregulated; and b) optionally a gene encoding Beta-galactoside alpha-2,6-sialyltransferase 1 inserted.
- the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 are inactivated and/or downregulated; and the gene encoding ST6Gal1 is inserted.
- the mammalian cell according to present invention has the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal4, St3Gal6, and FUT8 inactivated and/or downregulated.
- the mammalian cell according to present invention has the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8 inactivated and/or downregulated.
- the endogenous gene B3GNT2 is present.
- the mammalian cell according to present invention further has the endogenous B3GNT2 is inactivated and/or downregulated. It is to be understood that this may be in addition to any combination of other genes being inactivated and/or downregulated.
- the mammalian cell according to present invention further has the endogenous GLUL is inactivated and/or downregulated. It is to be understood that this may be in addition to any combination of other genes being inactivated and/or downregulated.
- the mammalian cell according to present invention is an in vitro cell 25 line, such as any one selected from the group consisting of a Chinese Hamster Ovarian (CHO) cells, such as CHO-K1, CHO-S, DG44; Baby Hamster Kidney (BHK) cell; COS cell; HEK293; NSO; SP2/0; YB2/0; HUVEC; HKB; PER-C6; NSO; or derivatives of any of these cells.
- CHO Chinese Hamster Ovarian
- the mammalian cell according to present invention has been further modified to express an exogenous human glycoprotein of interest, such as a therapeutic human protein.
- said exogenous human glycoprotein of interest is a human serum protein, such as a human serpin, such as human serpin selected from the list consisting of SERPINA1, SERPINA2, SERPINA3, SERPINA4, SERPINA5, SERPINA6, SERPINA7, SERPINA8, SERPINA9, SERPINA10, SERPINA11, SERPINA12, SERPINA13, SERPINB1, SERPINB2, SERPINB3, SERPINB4, SERPINB5, SERPINB6, SERPINB7, SERPINB8, SERPINB9, SERPINB10, SERPINB11, SERPINB12, SERPINB13, SERPINC1, SERPIND1, SERPINE1, SERPINE2, SERPINE3, SERPINF1, SERPINF2, SERPING1, SERPINH1, SERPINI1, and SER
- the mammalian cell according to present invention is a cell line producing said glycoprotein of interest with a primary n-glycan structure that is a fully sialylated bi-antennary structure without core fucosylation, such as with more than 80%, such as 82%, such as 84%, such as 86%, such as 88%, such as 90% of the glycoproteins of interest produced being in with a fully sialylated bi-antennary structure without core fucosylation.
- the mammalian cell according to present invention has a glycan structure according to the structure A2G2S2 with the following pictorial representations:
- the mammalian cell according to present invention has been further modified to express an exogenous human glycoprotein of interest, which exogenous human glycoprotein of interest is selected from Plasma protease C1 inhibitor (C1Inh) glycosylated at one or more positions selected from Asn3, Asn47, Asn59, Asn216, Asn231, Asn250, and Asn330; Antithrombin-III (ATIII) glycosylated at one or more positions selected from Asn96, Asn135, Asn155 and Asn192; and Human alpha-1-antitrypsin (AAT) glycosylated at one or more, such as two or three of the positions Asn46, Asn83, and Asn247.
- C1Inh Plasma protease C1 inhibitor
- AATIII Antithrombin-III glycosylated at one or more positions selected from Asn96, Asn135, Asn155 and Asn192
- AAT Human alpha-1-antitrypsin
- Plasmids 2632 (GFP_2A_Cas9) and 5920 (FUT8_681494) are described in Gray, L. M., Lee, 3. S., Gerling, S., Kallehauge, T. B., Hansen, A, H., Kol, S., Lee, G. M., Pedersen, L. E. and Kildegaard, H. F. (2015), One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnology Journal, 10: 1446-1456. doi10.1002/biot.201500027.
- Plasmids 2928 (MGAT4A_411545), 2933 (MGAT4B_1280368), 2937 (MGAT5_327084), 2940 (ST3GAL4_964386), 2943 (ST3GAL6_1812502), 4408 (B3gnt2 NW 003613880.1_1273293), 4412 (St3_gal3_NW_003613906.1_244730) and 4424 (Sppl3_NW_003613978.1_213040) were constructed as described in Ronda, C., Pedersen, L. E, Hansen, H. G., Kallehauge, T.
- sgRNA plasmid sgRNA1_C described in Ronda et al was used as template in the PCR reaction to generate the backbone of gRNA plasmids.
- St6Gal1 vector map is shown in FIG. 6 .
- SerpinA vector map is shown in FIG. 7 .
- SerpinG vector map is shown in FIG. 8 .
- SerpinC1 vector map is shown in FIG. 9 .
- N-glycan analysis was performed with GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, Mass.) according to the manufacturer's instruction. In this case 12 ⁇ l of 10 ⁇ concentrated (MWCO filtered, Amicon Ultra-15, Merck, Darmstadt, Germany) secretome or purified protein sample were used for each. Labeled N-Glycans were analyzed by a LC-MS system using a Thermo Ultimate 3000 HPLC with fluorescence detector coupled on-line to a Thermo Velos Pro Iontrap MS. Separation gradient 30% to 43% buffer and MS was run in positive mode.
- GFP_2A_Cas9 and single guide RNA (sgRNA) plasmids were constructed as previously described (Gray, L.M. et al., One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnol. J. 2015, 10, 1446-1456).
- the sgRNA target design for MGAT4A, MGAT4B, MGAT5, ST3GAL3, ST3GAL4, ST3GAL6, B3GNT2, FUT8, SPPL3 and GLUL was performed using “CRISPy” (Ronda, C.
- Oligos for sgRNA expression vector cloning Oligo Name Oligo sequence (5′ ⁇ > 3′) gRNA_MGAT4A_411545_fwd GGAAAGGACGAAACACCGTCTACA TTCGTCACTGTCGGTTTTAGAGCT AGAAAT (SEQ ID NO: 11) gRNA_MGAT4A_411545_rev CTAAAACGACAGTGACGAATGTAG ACCGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 12) gRNA_MGAT4B_1280368_fwd GGAAAGGACGAAACACCGCTTCAG TCGCGGATCCTCTGTTTTAGAGCT AGAAAT (SEQ ID NO: 13) gRNA_MGAT4B_1280368_rev CTAAAACAGAGGATCCGCGACTGA AGCGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 14) gRNA_MGAT5_327084_fwd
- Plasmids for co-expression of A1AT/C1INH and St6gal1 were constructed with uracil-specific excision reagent cloning method as previously described (Pristov ⁇ ek, N. et al., Using Titer and Titer Normalized to Confluence Are Complementary Strategies for Obtaining Chinese Hamster Ovary Cell Lines with High Volumetric Productivity of Etanercept. Biotechnol. J. 2018, 13; and Lund, A. M. et al., A Versatile System for USER Cloning-Based Assembly of Expression Vectors for Mammalian Cell Engineering. PLOS ONE 2014, 9(5): e96693).
- the DNA sequences of the plasmids are listed in FIG. 17 .
- CHO-S suspension cells were incubated in a humidified incubator at 120 rpm, 37° C., 5% CO2, passaged to 2-3 ⁇ 105 cells/mL every 2-3 days and transfected in 6-well plates (BD Biosciences, San Jose, Calif.) as described previously (Gray, L. M. et al., One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnol. J. 2015, 10, 1446-1456).
- the GFP_2A_Cas9/sgRNA plasmid ratios for each transfection was 1:1 of which the plasmid load of sgRNA was divided equally by the amount of different sgRNAs used per transfection (Table 5).
- pmaxGFP® vector (Lonza, Basel, Switzerland) transfection was performed as well. Cells were harvested for fluorescence-activated cell sorting (FACS) 48 h post transfection.
- Single fluorescent-positive (GFP) cells were sorted into 384-well plates (Corning, New York, N.Y.) containing 30 ⁇ L CD CHO medium supplemented with 8 mM L-glutamine, 1.5% HEPES buffer and 1% Antibiotic-Antimycotic (Gibco, Waltham, Mass.) per well as described previously (Hansen, H. G. et al, Case study on human alpha1 -antitrypsin: Recombinant protein titers obtained by commercial ELISA kits are inaccurate. Biotechnol. J. 2016, 11, 1648-1656).
- fluorescent-positive cell populations were gated based on non-transfected WT CHO-S cells. Two weeks after cell sorting cell colonies were moved to 96-well flat-bottom plates (BD Biosciences) and expanded for deep sequencing analysis and batch cultivation.
- the primers contain overhang sequences compatible with Illumina Nextera XT indexing (forward primeroverhang: TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAG (SEQ ID NO: 33), reverse primer overhang: GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAG(SEQ ID NO: 34)).
- Cell densities and viabilities were determined once per day using the NucleoCounter NC-250 Cell Counter (ChemoMetec). The cells were passaged in fresh selection medium every 2-3 days until viability and doubling time reached stable values. Polyclonal cell lines (pools) were seeded in duplicates at ⁇ 1 ⁇ 106 cells/mL with corresponding MSX concentrations. Cell densities and viabilities were determined once per day and supernatants of the pools were harvested three days after seeding and pooled within duplicates for purification of rhAlAT and rhC1INH.
- Non-stained single cells were sorted from pools as described above. For cell sorting, all viable cells were gated for sorting into 384-well plates with L-glutamine-free medium. Two weeks after cell sorting the clones were moved to 96-well flat-bottom plates (BD Biosciences) and expanded to shake flask format in CD CHO medium supplemented with 1pL/mL anti-clumping agent, 25 ⁇ M MSX and lacking L-glutamine.
- FITC SNA positive cells were washed with 200 ⁇ L CD CHO medium and then washed twice with 200 ⁇ L phosphate buffered saline (PBS) (300 g, 5 min, RT). The samples were resuspended in 200 ul PBS and transferred to 96-well plate for final centrifugation at 300 g for one minute. Percentage of FITC SNA positive cells was determined in a 96-well optical-bottom microplate (Greiner Bio-One, Frickenhausen, Germany) using a Celigo Imaging Cell Cytometer (Nexcelom Bioscience, Lawrence, Mass.).
- FITC SNA-positive cells were identified using the blue channel (Hoechst-positive cells), and the green channel (FITC SNA-positive cells) was used to detect cells with alpha-2,6-sialic acid linkage.
- a Hoechst/FITC SNA-stained CHO-S WT sample was gated to distinguish between FITC-positive and FITC-negative cells.
- rhA1AT and rhC1INH were purified using CaptureSelect affinity resins (Thermo Fisher Scientific) according to the manufacturer's instructions.
- rhA1AT was further purified by size exclusion chromatography on a Superdex 200 increase 10/300 GL column (GE Healthcare) equilibrated in PBS.
- rhA1AT and rhC1INH titers were determined using biolayer interferometry on an Octet RED96 (Pall, Menlo Park, Calif., USA) as described previously for A1AT (Noh, S. M. et al., Reduction of ammonia and lactate through the coupling of glutamine synthetase selection and downregulation of lactate dehydrogenase-A in CHO cells. Appl. Microbiol. Biotechnol. 2017, 101, 1035-1045).
- streptavidin biosensors (18-5021, Fortebio, Pall) were functionalized with CaptureSelect biotin anti-A1AT conjugate or CaptureSelect biotin anti-C1INH conjugate (Thermo Fisher Scientific) at 5 ⁇ g/mL in PBS, and blocked in PBS containing 1 ⁇ g/mL biocytin (600 and 300 s incubation steps, respectively).
- Regeneration was performed with 50 mM TRIS, 2 M MgCl2, pH 7.5. Assays were performed in 96-well black microplates (Greiner Bio-One, Kremsmünster, Austria). Octet System Data Analysis 7.1 software was used to calculate binding rates and absolute A1AT and C1INH concentrations.
- A1AT inhibitory activity was determined using the EnzChek Elastase Assay Kit (Molecular
- A1AT 8.0, 4.0, 2.0, 1.0, 0.5, 0.25, 0.13, and 0.06 ⁇ M
- DQ-elastin fluorescently labelled substrate
- C1INH inhibitory activity was determined using the Technochrom C1INH Assay Kit (TechnoClone, Vienna, Austria). In short, plasma containing C1INH activity (120%, 60%, 30%) and samples ( ⁇ 0.25 ⁇ M) were incubated with substrate-buffer mixture for 3 min at room temperature, after which 50% acetic acid was added. Extinction was measured at 405 nm.
- N-glycans were derivatized with GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, Mass.) according to the manufacturer's instruction. Briefly; 12 ⁇ g purified protein or 12 ⁇ l of 10 ⁇ concentrated (Amicon Ultra-15, Merck) secretome sample were used for each sample. Labeled N-Glycans were analyzed by LC-MS as described previously (Gray, L. M. et al., One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnol. J. 2015, 10, 1446-1456) Separation gradient from 30% to 43% 50 mM ammonium formate buffer and MS were run in positive mode. Amount of N-Glycan was measured by integrating the peaks with Thermo Xcalibur software (Thermo Fisher Scientific, Waltham, Mass.) giving the normalized, relative amount of the glycans.
- the aim of our study was to produce rhAlAT and rhC1INH in CHO cells with N-glycan profiles similar to human pIAlAT and pIC1INH.
- Our approach was to engineer the heterogeneous N-glycan profile of CHO-S WT cells towards a homogeneous A2G2S2 N-glycan structure, which is the predominant N-glycan on plA1AT/plC1INH.
- CHO-S WT reached maximal viable cell density of —6 ⁇ 106 cells/mL on day five and cell viability declined rapidly to ⁇ 50% on day 6.
- the 10 ⁇ KO A and 10x KO B clones had cell viabilities >75% until day 10 of the batch cultivation and reached higher maximal viable cell density than CHO-S WT.
- N-glycan analysis of the CHO-S WT secretome resulted in more than 25 N-glycan structures ( FIG. 12 B ) where the A2G2S2 structure with alpha-2,6-linked sialic acids, predominantly found on pIAlAT and pIC1INH, was not detected.
- the majority of CHO-S WT N-glycans contained core-fucosylation.
- the N-glycans produced by CHO-S WT cells appear diverse and comprise high-mannose structures as well as non-galactosylated, fully and partially sialylated di-, tri- and tetra-antennary structures (all with alpha-2,3-linked sialic acids).
- A2FG2S2 was found as the main N-glycan on total secreted proteins of CHO-S WT.
- the N-glycan profiles of 10 ⁇ KO A and 10 ⁇ KO B are more homogeneous ( FIG. 12 B ) with all structures lacking core-fucosylation.
- only relatively small amounts of CHO-specific alpha-2,3-linked sialylation were present.
- SNA lectins are reported to bind predominantly to sialic acids of N-glycans linked to the galactose residue in a human-like alpha-2,6-sialylation.
- Analyzing FITC-SNA-stained CHO-S WT we found relatively low levels of alpha-2,6-sialylation ( FIG. 13 A ).
- FITC-SNA stained CHO-S WT samples were used to gate between FITC-positive and FITC-negative cells.
- IEF gel analysis of rhC1INH produced in a CHO-S WT background resulted in isoforms with pI ranging from pH ⁇ 4-5.
- a high degree of heterogeneity was also found in purified rhClINH produced in clone C1-1.
- rhC1INH produced in clone C1-2 was less heterogeneous with pI at pH ⁇ 3.5 similar to pIC1INH.
- N-glycan analysis of purified rhA1AT and rhC1INH from CHO-S WT cells we detected a higher degree of heterogeneity compared to N-glycan structures on rhA1AT and rhC1INH from polyclonal 10 ⁇ KO cell pools.
- the polyclonal cell lines revealed two predominant sugar structures on both proteins (A2G2 and A2G2S2 N-glycans), whereas we could not detect the A2G2S2 structure on products from CHO-S WT.
- the amount of predominant N-glycan structures on rhAlAT and rhClINH was decreased from two (polyclonal pools) to one (monoclonal producers), identified as A2G2S2 N-glycan.
- All four 10 ⁇ KO-derived monoclonal cell lines produced rhAlAT and rhClINH with higher proportion of A2G2S2 structures than pIA1AT and pIC1INH ( FIG. 15 C ).
- the proportion of A2G2S2 in rhA1AT and rhC1INH was approximately 88-92% and 84%, respectively, and 82% for pIA1AT and 66% for pIC1INH.
- rhA1AT activity was determined by its inhibitory function of elastase activity ( FIG. 15 D ). Similar to p 1 A1AT, a decrease in elastase activity was detected at A1AT concentrations >0.1 ⁇ M for rhA1AT from1clones A1-1 and A1-2. In addition, 50% of elastase inhibition was reached at —0.3 pM A1AT for pIAlAT as well as rhAlAT. In vitro activity of purified rhClINH produced by clones C1-1 and C1-2 was similar or higher compared to pIC1INH.
- the supernatants were thawed and purified by affinity chromatography using a 1-mL anti-protein C affinity column for EPO and Clinhibitor, and the fractions containing the EPO and Clinhibitor respectively were pooled.
- N-glycan analysis was performed on the purified samples, with GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, Mass.) according to the manufacturer's instruction. In this case 12 ⁇ l of purified protein sample were used for each. Labeled N-Glycans were analyzed by a LC-MS system using a Thermo Ultimate 3000 HPLC with fluorescence detector coupled on-line to a Thermo Velos Pro Iontrap MS. Separation gradient 30% to 43% buffer and MS was run in positive mode.
Abstract
The present invention relates to the finding of methods to shift the glycosylation profile of recombinant produced serum glycoproteins to the predominant bi-antennary form found in human plasma. This is accomplished by providing a mammalian cell line according to the invention with a series of gene disruptions and/or gene insertions that facilitate this shift.
Description
- This application is a divisional of U.S. patent application Ser. No. 16/767,531, filed May 27, 2020, which in turn is a U.S. national stage of International Patent Application No. PCT/EP2018/081616, filed Nov. 16, 2018, which claims the benefit of European Patent Application No. 17204071.9, filed Nov. 28, 2017, and European Patent Application No. 18182948.2, filed Jul. 11, 2018, each of which are incorporated by reference in their entireties.
- Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: ASCII (text) file named “55685A_Seqlisting.XML,” 88,169 bytes, created on Nov. 14, 2022.
- The present invention relates to the finding of methods to shift the glycosylation profile of recombinant produced serum glycoproteins to the predominant bi-antennary form found in human plasma. This is accomplished by providing a mammalian cell line according to the invention with a series of knock outs and/or knock in's that facilitate this shift.
- Recombinant glycoproteins and in particular human serum proteins, such as the glycoproteins from the family of serpins are produced for a range of applications. This included Alpha-1-antitrypsin (AAT), Plasma protease C1 inhibitor (C1Inh), Antithrombin-III (ATIII), Monocyte neutrophil elastase inhibitor (Serpin B1), Plasminogen activator inhibitor I (PAI1) that are produced for therapeutic applications in humans.
- Alpha-1-antitrypsin (AAT) is used for treatment of people with AAT-deficiency. Such deficiency may result in lethal lung disease and liver disease. Over one million people have been estimated to be deficient of AAT globally. Currently, AAT is purified from human plasma.
- This treatment regimen is both expensive (USD 52,000 per year per patient), and not optimal with regards to safety, as possible pathogens present in plasma may not be efficiently cleared.
- Many approaches have been pursued to produce recombinant human AAT. Efforts of producing AAT in non-mammalian cells such as E.coli, yeast and plants have resulted in either non-glycosylated AAT or non-human glycosylation patterns. Production of AAT in transgenic animals such as sheep has also been reported. However, an immune response to endogenous (sheep) AAT in the purified product was later observed. This clearly demonstrates one of the major challenges that transgenic animal-derived therapeutics is facing. Finally, AAT has also been produced in CHO and human cells with an aberrant glycoprofile.
- Thus, there is a need in the art for glycoproteins with a more native human glycoprofile.
- It is an object of embodiments of the invention to provide methods and tools for producing recombinant proteins with a glycan profile found naturally in humans.
- It has been found by the present inventor(s) that by specific modification of a mammalian host cell with the downregulation or inactivation of a series of genes in combination with the insertion of other specific gene(s), this mammalian host cell is made into a cell that will produce glycoproteins with a glycosylation profile that more resemble the glycosylation profile found for the same glycoproteins naturally in humans, such as in human plasma.
- So, in a first aspect the present invention relates to a recombinant mammalian cell line having a) one or more of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 inactivated and/or downregulated; and b) optionally a gene encoding Beta-galactoside alpha-2,6-
sialyltransferase 1 inserted. - In some embodiments the endogenous gene Mgat4A is inactivated and/or downregulated.
- In some embodiments the endogenous gene Mgat4B is inactivated and/or downregulated.
- In some embodiments the endogenous gene Mgat5 is inactivated and/or downregulated.
- In some embodiments the endogenous gene St3Gal3 is inactivated and/or downregulated.
- In some embodiments the endogenous gene St3Gal4 is inactivated and/or downregulated.
- In some embodiments the endogenous gene St3Gal6 is inactivated and/or downregulated.
- In some embodiments the endogenous gene SPPL3 inactivated and/or downregulated.
- In some embodiments the endogenous gene B3GNT2 is inactivated and/or downregulated.
- In some embodiments the endogenous gene GLUL is inactivated and/or downregulated.
- In some embodiments the endogenous gene FUT8 is inactivated and/or downregulated.
- In some embodiments, two, three, four, five, six, seven, or all eight of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 are inactivated and/or downregulated.
- In some embodiments, two, three, four, five, six, seven, eight, or all nine of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, B3GNT2, and FUT8 are inactivated and/or downregulated.
- In some embodiments, two, three, four, five, six, seven, eight, or all nine of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, GLUL and FUT8 are inactivated and/or downregulated.
- In some embodiments, two, three, four, five, six, seven, eight, nine, or all ten of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, B3GNT2, GLUL and FUT8 are inactivated and/or downregulated.
- In some embodiments two genes selected from Mgat4A and Mgat4B;
-
- Mgat4A and Mgat5; Mgat4A and St3Gal3; Mgat4A and St3Gal4; Mgat4A and St3Gal6;
- Mgat4A and SPPL3;Mgat4A and FUT8; GLUL and Mgat4A; GLUL and Mgat4B; GLUL and Mgat5; GLUL and St3Gal3; GLUL and St3Gal4; GLUL and St3Gal6;GLUL and SPPL3;GLUL and FUT8; Mgat4B and Mgat5; Mgat4B and St3Gal3; Mgat4B and St3Gal4; Mgat4B and St3Gal6;
- Mgat4B and SPPL3; Mgat4B and FUT8;Mgat5 and St3Gal3; Mgat5 and St3Gal4;Mgat5 and St3Gal6; Mgat5 and SPPL3; Mgat5 and FUT8; St3Gal3 and St3Gal4; St3Gal3 and St3Gal6;
- St3Gal3 and SPPL3; St3Gal3 and FUT8; St3Gal4 and St3Gal6; St3Gal4 and SPPL3; St3Gal4 and FUT8; St3Gal6 and SPPL3; St3Gal6 and FUT8; and SPPL3 and FUT8 are inactivated and/or downregulated.
- In some embodiments three genes selected from
-
- Mgat4A, Mgat4B, and Mgat5; Mgat4A, Mgat4B, and St3Gal3;
- Mgat4A, Mgat4B, and St3Gal4; Mgat4A, Mgat4B, and St3Gal6;
- Mgat4A, Mgat4B, and SPPL3; Mgat4A, Mgat4B, and FUT8; Mgat4A, Mgat5, and St3Gal3;
- Mgat4A, Mgat5, and St3Gal4; Mgat4A, Mgat5, and St3Gal6;
- Mgat4A, Mgat5, and SPPL3; Mgat4A, Mgat5, and FUT8; Mgat4A, St3Gal3, and St3Gal4;
- Mgat4A, St3Gal3, and St3Gal6; Mgat4A, St3Gal3, and SPPL3; Mgat4A, St3Gal3, and FUT8;
- Mgat4A, St3Gal4, and St3Gal6; Mgat4A, St3Gal4, and SPPL3; Mgat4A, St3GaI4, and FUT8;
- Mgat4A, St3Gal6, and SPPL3; Mgat4A, St3Gal6, and FUT8; Mgat4A, SPPL3, and FUT8; GLUL, Mgat4B, and Mgat5; GLUL, Mgat4B, and St3Gal3; GLUL, Mgat4B, and St3Gal4; GLUL, Mgat4B, and St3Gal6; GLUL, Mgat4B, and SPPL3; GLUL, Mgat4B, and FUT8; GLUL, Mgat5, and St3Gal3; GLUL, Mgat5, and St3Gal4; GLUL, Mgat5, and St3Gal6; GLUL, Mgat5, and SPPL3; GLUL, Mgat5, and FUT8; GLUL, St3Gal3, and St3Gal4; GLUL, St3Gal3, and St3Gal6;
- GLUL, St3GaI3, and SPPL3; GLUL, St3Gal3, and FUT8; GLUL, St3Gal4, and St3Gal6; GLUL, St3Gal4, and SPPL3; GLUL, St3Gal4, and FUT8; GLUL, St3Gal6, and SPPL3; GLUL, St3Gal6, and FUT8; GLUL, SPPL3, and FUT8; GLUL, Mgat4A and Mgat4B; GLUL, Mgat4A and Mgat5;
- GLUL, Mgat4A and St3Gal3; GLUL, Mgat4A and St3Gal4; GLUL, Mgat4A and St3Gal6; GLUL, Mgat4A and SPPL3; GLUL, Mgat4A and FUT8; Mgat4B, Mgat5, and St3Gal3; Mgat4B, Mgat5, and St3Gal4; Mgat4B, Mgat5, and St3Gal6;
- Mgat4B, Mgat5, and SPPL3; Mgat4B, Mgat5, and FUT8; Mgat4B, St3Gal3, and St3Gal4;
- Mgat4B, St3Gal3, and St3Gal6; Mgat4B, St3Gal3, and SPPL3; Mgat4B, St3Gal3, and FUT8;
- Mgat4B, St3Gal4, and St3Gal6; Mgat4B, St3Gal4, and SPPL3; Mgat4B, St3Gal4, and FUT8;
- Mgat4B, St3Gal6, and SPPL3; Mgat4B, St3Gal6, and FUT8; Mgat4B, SPPL3, and FUT8; Mgat5, St3Gal3, and St3Gal4; Mgat5, St3Gal3, and St3Gal6; Mgat5, St3Gal3, and SPPL3;
- Mgat5, St3Gal3, and FUT8; Mgat5, St3Gal4, and St3Gal6; Mgat5, St3Gal4, and SPPL3;
- Mgat5, St3Gal4, and FUT8; Mgat5, St3Gal6, and SPPL3; Mgat5, St3Gal6, and FUT8; Mgat5, SPPL3, and FUT8; St3Gal3, St3Gal4, and St3Gal6; St3Gak3, St3Gao4, and SPPL3;
- St3Gal3, St3Gal4, and FUT8; St3Gal3, St3Gal6, and SPPL3; St3Gal3, St3Gal6, and FUT8;
- St3Gal3, SPPL3, and FUT8; St3Gak4, St3Gal6, and SPPL3; St3Gal4, St3Gal6, and FUT8;
- St3Gal4, SPPL3, and FUT8; and St3Gal6, SPPL3, and FUT8 are inactivated and/or downregulated.
- In some embodiments four genes selected from Mgat4A, Mgat4B, Mgat5, and St3Gal3;
-
- Mgat4A, Mgat4B, Mgat5, and St3Gal4; Mgat4A, Mgat4B, Mgat5, and St3Gal6;
- Mgat4A, Mgat4B, Mgat5, and SPPL3; Mgat4A, Mgat4B, Mgat5, and FUT8; Mgat4A, Mgat4B, St3Gal3, and St3Gal4; Mgat4A, Mgat4B, St3Gal3, and St3Gal6; Mgat4A, Mgat4B, St3Gal3, and SPPL3; Mgat4A, Mgat4B, St3Gal3, and FUT8; Mgat4A, Mgat4B, St3Gal4, and St3Gal6,
- Mgat4A, Mgat4B, St3Gal4, and SPPL3; Mgat4A, Mgat4B, St3Gal4, and FUT8; Mgat4A, Mgat4B, St3Gal6, and SPPL3; Mgat4A, Mgat4B, St3Gal6, and FUT8; Mgat4A, Mgat4B, SPPL3, and FUT8; Mgat4A, Mgat5, St3Gal3, and St3Gal4; Mgat4A, Mgat5, St3Gal3, and St3Gal6; Mgat4A, Mgat5, St3Gal3, and SPPL3; Mgat4A, Mgat5, St3Gal3, and FUT8; Mgat4A, Mgat5, St3Gal4, and St3Gal6; Mgat4A, Mgat5, St3Gal4, and SPPL3; Mgat4A, Mgat5, St3Gal4, and FUT8; Mgat4A, Mgat5, St3Gal6, and SPPL3; Mgat4A, Mgat5, St3Gal6, FUT8; Mgat4A, Mgat5, SPPL3, and FUT8; Mgat4A, St3Gal3, St3Gal4, and St3Gal6; Mgat4A, St3Gal3, St3Gal4, and SPPL3; Mgat4A, St3Gal3, St3Gal4, and FUT8; Mgat4A, St3Gal3, St3Gal6, and SPPL3;
- Mgat4A, St3Gal3, St3Gal6, and FUT8; Mgat4A, St3Gal3, SPPL3, and FUT8; Mgat4A, St3Gal4, St3Gal6, and SPPL3; Mgat4A, St3Gal4, St3Gal6, and FUT8; Mgat4A, St3Gal4, SPPL3, and FUT8; Mgat4A, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4B, Mgat5, and St3Gal3; GLUL, Mgat4B, Mgat5, and St3Gal4; GLUL, Mgat4B, Mgat5, and St3Gal6; GLUL, Mgat4B, Mgat5, and SPPL3; GLUL, Mgat4B, Mgat5, and FUT8; GLUL, Mgat4B, St3Gal3, and St3Gal4; GLUL, Mgat4B, St3Gal3, and St3Gal6; GLUL, Mgat4B, St3Gal3, and SPPL3; GLUL, Mgat4B, St3Gal3, and FUT8; GLUL, Mgat4B, St3Gal4, and St3Gal6, GLUL, Mgat4B, St3Gal4, and SPPL3; GLUL, Mgat4B, St3Gal4, and FUT8; GLUL, Mgat4B, St3Gal6, and SPPL3; GLUL, Mgat4B, St3Gal6, and FUT8; GLUL, Mgat4B, SPPL3, and FUT8; GLUL, Mgat5, St3Gal3, and St3Gal4; GLUL, Mgat5, St3Gal3, and St3Gal6; GLUL, Mgat5, St3Gal3, and SPPL3; GLUL, Mgat5, St3Gal3, and FUT8; GLUL, Mgat5, St3Gal4, and St3Gal6; GLUL, Mgat5, St3Gal4, and SPPL3; GLUL, Mgat5, St3Gal4, and FUT8; GLUL, Mgat5, St3Gal6, and SPPL3; GLUL, Mgat5, St3Gal6, FUT8; GLUL, Mgat5, SPPL3, and FUT8; GLUL, St3Gal3, St3Gal4, and St3Gal6; GLUL, St3Gal3, St3Gal4, and SPPL3; GLUL, St3Gal3, St3Gal4, and FUT8; GLUL, St3Gal3, St3Gal6, and SPPL3; GLUL, St3Gal3, St3Gal6, and FUT8; GLUL, St3Gal3, SPPL3, and FUT8; GLUL, St3Gal4, St3Gal6, and SPPL3; GLUL, St3Gal4, St3Gal6, and FUT8; GLUL, St3Gal4, SPPL3, and FUT8; GLUL, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4A, Mgat4B, and Mgat5; GLUL, Mgat4A, Mgat4B, and St3Gal3;
- GLUL, Mgat4A, Mgat4B, and St3Gal4; GLUL, Mgat4A, Mgat4B, and St3Gal6; GLUL, Mgat4A, Mgat4B, and SPPL3; GLUL, Mgat4A, Mgat4B, and FUT8; GLUL, Mgat4A, Mgat5, and St3Gal3;
- GLUL, Mgat4A, Mgat5, and St3Gal4; GLUL, Mgat4A, Mgat5, and St3Gal6; GLUL, Mgat4A, Mgat5, and SPPL3; GLUL, Mgat4A, Mgat5, and FUT8; GLUL, Mgat4A, St3Gal3, and St3Gal4;
- GLUL, Mgat4A, St3Gal3, and St3Gal6; GLUL, Mgat4A, St3Gal3, and SPPL3; GLUL, Mgat4A, St3Gal3, and FUT8; GLUL, Mgat4A, St3Gal4, and St3Gal6; GLUL, Mgat4A, St3Gal4, and SPPL3; GLUL, Mgat4A, St3Gal4, and FUT8; GLUL, Mgat4A, St3Gal6, and SPPL3; GLUL, Mgat4A, St3Gal6, and FUT8; Mgat4B, Mgat5, St3Gal3, and St3Gal4;Mgat4B, Mgat5, St3Gal3, and St3Gal6; Mgat4B, Mgat5, St3Gal3, and SPPL3; Mgat4B, Mgat5, St3Gal3, and FUT8; Mgat4B, Mgat5, St3Gal4, and St3Gal6; Mgat4B, Mgat5, St3Gal4, and SPPL3; Mgat4B, Mgat5, St3Gal4, and FUT8; Mgat4B, Mgat5, St3Gal6, and SPPL3;
- Mgat4B, Mgat5, St3Gal6, and FUT8; Mgat4B, Mgat5, SPPL3, and FUT8; Mgat4B, St3Gal3, St3Gal4, and St3Gal6; Mgat4B, St3Gal3, St3Gal4, and SPPL3; Mgat4B, St3Gal3, St3Gal4, and FUT8; Mgat4B, St3Gal3, St3Gal6, and SPPL3; Mgat4B, St3Gal3, St3Gal6, and FUT8;
- Mgat4B, St3Gal3, SPPL3, and FUT8; Mgat4B, St3Gal4, St3Gal6, and SPPL3; Mgat4B, St3Gal4, St3Gal6, and FUT8; Mgat4B, St3Gal4, SPPL3, and FUT8; Mgat4B, St3Gal6, SPPL3, and FUT8; Mgat5, St3Gal3, St3Gal4, and St3Gal6; Mgat5, St3Gal3, St3Gal4, and SPPL3;
- Mgat5, St3Gal3, St3, and FUT8; Mgat5, St3Gal3, St3Gal6, and SPPL3; Mgat5, St3Gal3, St3Gal6, and FUT8; Mgat5, St3Gal3, SPPL3, and FUT8; Mgat5, St3Gal4, St3Gal6, and SPPL3;
- Mgat5, St3Gal4, St3Gal6, and FUT8; Mgat5, St3Gal4, SPPL3, and FUT8; Mgat5, St3Gal6, SPPL3, and FUT8; St3Gal3, St3Gal4, St3Gal6, and SPPL3; St3Gal3, St3Gal4, St3Gal6, and FUT8; St3Gal3, St3Gal4, SPPL3, and FUT8; St3Gal3, St3Gal6, SPPL3, and FUT8; and St3Gal4, St3Gal6, SPPL3, and FUT8 are inactivated and/or downregulated.
- In some embodiments five genes selected from Mgat4A, Mgat4B, Mgat5, St3Gal3, and St3Gal4; Mgat4A, Mgat4B, Mgat5, St3Gal3, and St3Gal6; Mgat4A, Mgat4B, Mgat5, St3Gal3, and SPPL3; Mgat4A, Mgat4B, Mgat5, St3Gal3, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal4, and St3Gal6; Mgat4A, Mgat4B, Mgat5, St3Gal4, and SPPL3; Mgat4A, Mgat4B, Mgat5, St3Gal4, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal6, and SPPL3; Mgat4A, Mgat4B, Mgat5, St3Gal6, and FUT8; Mgat4A, Mgat4B, Mgat5, SPPL3, and FUT8; Mgat4A, Mgat5, St3Gal3, St3Gal4, and St3Gal6; Mgat4A, Mgat5, St3Gal3, St3Gal4, and SPPL3; Mgat4A, Mgat5, St3Gal3, St3Gal4, and FUT8; Mgat4A, Mgat5, St3Gal3, St3Gal6, and SPPL3; Mgat4A, Mgat5, St3Gal3, St3Gal6, and FUT8; Mgat4A, Mgat5, St3Gal3, SPPL3, and FUT8; Mgat4A, St3Gal3, St3Gal4, St3Gal6, and SPPL3; Mgat4A, St3Gal3, St3Gal4, St3Gal6, and FUT8; Mgat4A, St3Gal3, St3Gal4, SPPL3, and FUT8; Mgat4A, St3Gal4, St3Gal6, SPPL3, and FUT8;
- GLUL, Mgat4B, Mgat5, St3Gal3, and St3Gal4; GLUL, Mgat4B, Mgat5, St3Gal3, and St3Gal6;
-
- GLUL, Mgat4B, Mgat5, St3Gal3, and SPPL3; GLUL, Mgat4B, Mgat5, St3Gal3, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal4, and St3Gal6; GLUL, Mgat4B, Mgat5, St3Gal4, and SPPL3; GLUL, Mgat4B, Mgat5, St3Gal4, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal6, and SPPL3; GLUL, Mgat4B, Mgat5, St3Gal6, and FUT8; GLUL, Mgat4B, Mgat5, SPPL3, and FUT8; GLUL, Mgat5, St3Gal3, St3Gal4, and St3Gal6; GLUL, Mgat5, St3Gal3, St3Gal4, and SPPL3; GLUL, Mgat5, St3Gal3, St3Gal4, and FUT8; GLUL, Mgat5, St3Gal3, St3Gal6, and SPPL3; GLUL, Mgat5, St3Gal3, St3Gal6, and FUT8; GLUL, Mgat5, St3Gal3, SPPL3, and FUT8; GLUL, St3Gal3, St3Gal4, St3Gal6, and SPPL3; GLUL, St3Gal3, St3Gal4, St3Gal6, and FUT8; GLUL, St3Gal3, St3Gal4, SPPL3, and FUT8; GLUL, St3Gal4, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal3, and St3Gal4; GLUL, Mgat4A, Mgat5, St3Gal3, and St3Gal6; GLUL, Mgat4A, Mgat5, St3Gal3, and SPPL3; GLUL, Mgat4A, Mgat5, St3Gal3, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal4, and St3Gal6; GLUL, Mgat4A, Mgat5, St3Gal4, and SPPL3; GLUL, Mgat4A, Mgat5, St3Gal4, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal6, and SPPL3; GLUL, Mgat4A, Mgat5, St3Gal6, and FUT8; GLUL, Mgat4A, Mgat5, SPPL3, and FUT8; St3Gal3, St3Gal4, and St3Gal6; GLUL, Mgat4A, St3Gal3, St3Gal4, and SPPL3; GLUL, Mgat4A, St3Gal3, St3Gal4, and FUT8; GLUL, Mgat4A, St3Gal3, St3Gal6, and SPPL3; GLUL, Mgat4A, St3Gal3, St3Gal6, and FUT8; St3Gal3, SPPL3, and FUT8; GLUL, Mgat4A, St3Gal4, St3Gal6, and SPPL3; GLUL, Mgat4A, St3Gal4, St3Gal6, and FUT8; GLUL, Mgat4A, St3Gal4, SPPL3, and FUT8; and GLUL, Mgat4A, St3Gal6, SPPL3, and FUT8; Mgat4B, Mgat5, St3Gal3, St3Gal4, and St3Gal6;
- Mgat4B, Mgat5, St3Gal3, St3Gal4, and SPPL3; Mgat4B, Mgat5, St3Gal3, St3Gal4, and FUT8;
- Mgat4B, Mgat5, St3Gal3, St3Gal6, and SPPL3; Mgat4B, Mgat5, St3Gal3, St3Gal6, and FUT8;
- Mgat4B, Mgat5, St3Gal3, SPPL3, and FUT8; Mgat4B, St3Gal3, St3Gal4, St3Gal6, and SPPL3;
- Mgat4B, St3Gal3, St3Gal4, St3Gal6, and FUT8; Mgat4B, St3Gal3, St3Gal4, SPPL3, and FUT8;
- Mgat4B, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat5, St3Gal3, St3Gal4, St3Gal6, and SPPL3;
- Mgat5, St3Gal3, St3Gal4, St3Gal6, and FUT8; Mgat5, St3Gal3, St3Gal4, SPPL3, and FUT8;
- Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8; and St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 are inactivated and/or downregulated.
- In some embodiments six genes selected from Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4B, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4B, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4B, Mgat5, St3Gal3, St3Gal6, SPPL3, and FUT8; Mgat4B, Mgat5, St3Gal3, St3Gal4, SPPL3, and FUT8; Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, FUT8; Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3; Mgat4A, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4A, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4A, Mgat5, St3Gal3, St3Gal6, SPPL3, and FUT8; Mgat4A, Mgat5, St3Gal3, St3Gal4, SPPL3, and FUT8; Mgat4A, Mgat5, St3Gal3, St3Gal4, St3Gal6, and FUT8; Mgat4A, Mgat5, St3Gal3, St3Gal4, St3Gal6, and SPPL3; Mgat4A, Mgat4B, St3Gal4, St3Gal6, SPPL3, and FUT8;
-
- Mgat4A, Mgat4B, St3Gal3, St3Gal6, SPPL3, and FUT8; Mgat4A, Mgat4B, St3Gal3, St3Gal4, SPPL3, and FUT8; Mgat4A, Mgat4B, St3Gal3, St3Gal4, St3Gal6, and FUT8; Mgat4A, Mgat4B, St3Gal3, St3Gal4, St3Gal6, and SPPL3; Mgat4A, Mgat4B, Mgat5, St3Gal6, SPPL3, and FUT8;
- Mgat4A, Mgat4B, Mgat5, St3Gal4, SPPL3, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal4, St3Gal6, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal4, St3Gal6, and SPPL3; Mgat4A, Mgat4B, Mgat5, St3Gal3, SPPL3, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal6, and FUT8;
- Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal6, and SPPL3; Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, and SPPL3; and Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, and St3Gal6; GLUL, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; GLUL, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8; GLUL, Mgat5, St3Gal3, St3Gal6, SPPL3, and FUT8; GLUL, Mgat5, St3Gal3, St3Gal4, SPPL3, and FUT8; GLUL, Mgat5, St3Gal3, St3Gal4, St3Gal6, and FUT8; GLUL, Mgat5, St3Gal3, St3Gal4, St3Gal6, and SPPL3; GLUL, Mgat4B, St3Gal4, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4B, St3Gal3, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4B, St3Gal3, St3Gal4, SPPL3, and FUT8; GLUL, Mgat4B, St3Gal3, St3Gal4, St3Gal6, and FUT8; GLUL, Mgat4B, St3Gal3, St3Gal4, St3Gal6, and SPPL3; GLUL, Mgat4B, Mgat5, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal4, SPPL3, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal4, St3Gal6, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal4, St3Gal6, and SPPL3; GLUL, Mgat4B, Mgat5, St3Gal3, SPPL3, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal3, St3Gal6, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal3, St3Gal6, and SPPL3;
- GLUL, Mgat4B, Mgat5, St3Gal3, St3Gal4, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal3, St3Gal4, and SPPL3; and GLUL, Mgat4B, Mgat5, St3Gal3, St3Gal4, and St3Gal6; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, and St3Gal4; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, and
- St3Gal6; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, and SPPL3; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, and FUT8; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal4, and St3Gal6; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal4, and SPPL3; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal4, and FUT8; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal6, and SPPL3; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal6, and FUT8; GLUL, Mgat4A, Mgat4B, Mgat5, SPPL3, and FUT8; GLUL, Mgat4A, Mgat4B, St3Gal3, St3Gal4, and St3Gal6; GLUL, Mgat4A, Mgat4B, St3Gal3, St3Gal4, and SPPL3; GLUL, Mgat4A, Mgat4B, St3Gal3, St3Gal4, and FUT8; GLUL, Mgat4A, Mgat4B, St3Gal3, St3Gal6, and SPPL3; GLUL, Mgat4A, Mgat4B, St3Gal3, St3Gal6, and FUT8; GLUL, Mgat4A, Mgat4B, St3Gal3, SPPL3, and FUT8; GLUL, Mgat4A, Mgat4B, St3Gal4, St3Gal6, and SPPL3; GLUL, Mgat4A, Mgat4B, St3Gal4, St3Gal6, and FUT8; GLUL, Mgat4A, Mgat4B, St3Gal4, SPPL3, and FUT8; GLUL, Mgat4A, Mgat4B, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4A, Mgat4B, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal3, St3Gal4, and St3Gal6; GLUL, Mgat4A, Mgat5, St3Gal3, St3Gal4, and SPPL3; GLUL, Mgat4A, Mgat5, St3Gal3, St3Gal4, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal3, St3Gal6, and SPPL3; GLUL, Mgat4A, Mgat5, St3Gal3, St3Gal6, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal3, SPPL3, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal4, St3Gal6, and SPPL3; GLUL, Mgat4A, Mgat5, St3Gal4, St3Gal6, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal4, SPPL3, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4A, St3Gal3, St3Gal4, St3Gal6, and SPPL3; St3Gal3, St3Gal4, St3Gal6, and FUT8; GLUL, Mgat4A, St3Gal3, St3Gal4, SPPL3, and FUT8; St3Gal3, St3Gal6, SPPL3, and FUT8; and GLUL, Mgat4A, St3Gal4, St3Gal6, SPPL3, and FUT8 are inactivated and/or downregulated.
- In some embodiments seven genes selected from Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, and SPPL3: Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, and FUT8;
-
- Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, SPPL3, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal6, SPPL3, and FUT8; Mgat4A, Mgat4B, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4A, Mgat4B, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; Mgat4A, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, and SPPL3: GLUL, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal3, St3Gal4, SPPL3, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal3, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4B, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8;
- GLUL, Mgat4B, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; GLUL, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, and St3Gal6; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, and SPPL3; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, and FUT8; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal6, and SPPL3; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal6, and FUT8; GLUL, Mgat4A, Mgat4B, Mgat5, St3Gal3, SPPL3, and FUT8; GLUL, Mgat4A, Mgat4B, St3Gal3, St3Gal4, St3Gal6, and SPPL3; GLUL, Mgat4A, Mgat4B, St3Gal3, St3Gal4, St3Gal6, and FUT8;
- GLUL, Mgat4A, Mgat4B, St3Gal3, St3Gal4, SPPL3, and FUT8; GLUL, Mgat4A, Mgat4B, St3Gal4, St3Gal6, SPPL3, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal3, St3Gal4, St3Gal6, and SPPL3; GLUL, Mgat4A, Mgat5, St3Gal3, St3Gal4, St3Gal6, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal3, St3Gal4, SPPL3, and FUT8; GLUL, Mgat4A, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8; and GLUL, Mgat4A, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8; and Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 are inactivated and/or downregulated.
- In some embodiments the gene encoding Beta-galactoside alpha-2,6-
sialyltransferase 1 is inserted. - In a second aspect, the present invention relates to a method for the production of a recombinant protein of interest, the method comprising the steps of: a) culturing a population of recombinant mammalian cells according to any one of claims 4-8 in a suitable cell culture medium; and b) harvesting said human protein of interest from the cell culture or cell culture medium. In some embodiments the protein of interest is produced with a glycan structure similar or identical to the glycan profile of said glycoprotein of interest found in human plasma.
- In a third aspect the present invention relates to a recombinant human glycoprotein of interest produced according to the method of the invention.
-
FIG. 1 . Illustration of glycosylation profile with a fully sialylated bi-antennary structure without core fucosylation as found e.g. in human AAT from various sources, such as plasma-purified AAT. -
FIG. 2 . Comparison of the glycoprofile of plasma-purified AAT and CHO-produced AAT. Wild-type CHO-produced AAT contains many different structures, with a core-fucosylated and partially to fully sialylated bi-antennary structure as the most dominant species, while plasma-purified contains almost exclusively a non-core-fucosylated fully sialylated bi-antennary glycostructure. In addition, CHO-derived sialic acids are linked by α2-3 linkages, while plasma sialic acids are linked by α2-6 linkages. -
FIG. 3 . Glycoprofile of human AAT derived from the engineered cell lines described here. The described gene disruptions and gene insertion results in a non-core-fucosylated fully sialylated bi-antennary glycostructure with α2-6 linked sialic acids as the predominant species. -
FIG. 4 . Isoelectric focusing gel of AAT derived from plasma (lane 1 and 2), the glycoengineered cell lines described here (lane 3 and 4), and wild-type CHO (lane 5 and 6). Migration patterns of plasma- and glycoengineered CHO-derived are identical. -
FIG. 5 . Elastase inhibition assay probing the activity of -
FIG. 6 . St6Gal1 vector map -
FIG. 7 . SerpinA vector map -
FIG. 8 . SerpinG vector map -
FIG. 9 . SerpinC1 vector map -
FIG. 10 . Combined St6Gal1/SerpinA vector map -
FIG. 11 . Combined St6Gal1/SerpinG vector map -
FIG. 12 . Growth and N-glycan structures from CHO-S WT and 10×KO cell lines. (A) Viable cell density and viability of batch cultures of CHO-S WT and two clonal cell lines with functional knockout of eight glycosyltransferases as well as GS and SPPL3. Error bars indicate the standard deviation of triplicates. (B) N-glycan analysis of total secreted proteins from CHO-S WT and the 10×KO clones A and B. Elution time is indicated on the x-axis and y-axis represents signal intensity normalized to highest peak (C) Proportion of non-fucosylated, biantennary N-glycans with terminal galactose (A2G2) in total secreted proteins from CHO-S WT and 10×KO clone A and B. -
FIG. 13 . FITC-SNA lectin staining of selected poly- and monoclonal cell lines. (A) Fluorescent images of CHO-S WT and A1-1 cell line. Cells were stained for alpha-2,6-sialic acid linkage with FITC-SNA (green) and for nuclei with Hoechst (blue). The bottom right corner bar displays a length of 500 μm (B) Comparison of FITC-SNA positive cells. FITC-SNA lectin staining of CHO-S WT, two 50 μM MSX polyclonal cell lines and four selected clones. Bars indicate the proportion of cells with positive FITC signal due to SNA lectin binding on alpha-2,6-linked sialic acids on the cell surface. Error bars represent standard deviation of three individual measurements per sample. -
FIG. 14 . Growth profiles, product titers and specific productivities of selected producing and non-producing clones. (A) Viable cell densities and cell viabilities of CHO-S WT, 10×KO B the rhA1AT-(A1-1 and A1-2) and rhCiINH- C1-1 and C1-2) producing clonal cell lines measured in batch cultures. Error bars indicate range of duplicate parallel cultures. (B) rhA1AT and rhC1INH titer in supernatants during the batch culture experiment. Error bars indicate standard deviation of three individual measurements from two shake flasks per clone. (C) Specific productivities of the rhAlAT and rhCiINH-producing clonal cell lines in the batch culture experiment. Average specific productivity was calculated from day 2-5 and from day 6-9. Colored symbols represent average measured specific productivity for shake flask duplicates. Black lines shows the average specific productivity based on the three measurements of shake flask duplicates. -
FIG. 15 . Characterization of purified rhAlAT and rhC1INH. (A) SDS-PAGE gel analysis of commercially available Cinryze (pIC1INH) and Prolastin-C (plA1AT) as well as rhA1AT and rhC1INH purified from polyclonal CHO-S WT or from monoclonal cell lines derived from 10×KO B. Removal of N-glycans by PNGaseF was performed where indicated. PNGaseF migrating as a ˜40 kDa band is indicated with an asterisk and impurities of pIC1INH are indicated with arrows. (B) IEF gel analysis of same proteins as described for panel A. 2.5 μg purified protein was analysed per sample if not indicated otherwise. (C) N-glycan structures annotated in clones A1-1 and C1-1, respectively, as well as A2G2S2 proportions of purified rhAlAT and rhC1INH compared to pIAlAT and pIC1INH. (D) Left panel: In vitro assay measuring the inhibition of elastase activity at different concentrations of pIAlAT and rhA1AT purified from clones A1-1 and A1-2. Error bars indicate range of duplicate measurements. Maximum proteolytic activity of porcine elastase was set to 100%. Right panel: In vitro activity assessment of pIC1INH and rhCiINH purified from clones C1-1 and C1-2. As described in the assay, 1 IU/ml C1INH activity was set to 100%. Error bars indicate range of duplicate measurements. -
FIG. 16 . N-glycan profiles, Overlay of CHO-S WT (dotted line) and Sppl3 KO (solid line) cell lines producing EPO and C1inh respectively. The effect of Sppl3 can be seen as a shift to larger N-glycans. -
FIG. 17 . is a Table reciting nucleotide sequences for overexpression vectors referenced in Example 4. - Glyco-analysis of human AAT from various sources revealed that plasma-purified AAT is glycosylated with a fully sialylated bi-antennary structure without core fucosylation (
FIGS. 1 and 2 ). In contrast, CHO-produced AAT contains many different structures with a partially and fully sialylated bi-antennary structure with core fucosylation as the most dominant species (FIG. 2 ). - The inventors of the present invention have found that a shift of the glycosylation profile of recombinant produced serum glycoproteins towards the predominant bi-antennary form found in human plasma, may be accomplished by knocking out or in any other way downregulating a selected a set of glycosylating enzymes. This will result in a 6, 7, 8, 9, 10 or 8-9 double knock out clone in which, glycoproteins, such as human serum proteins, such as human AAT are expressed. The following targets have been selected for this cell line:
-
- 1) Inactivation and/or downregulation of a series of enzymes Mgat4A, Mgat4B, and Mgat5 that that facilitate a decrease in branching.
- 2) Inactivation and/or downregulation of a series of enzymes St3Gal3, St3Gal4, and St3Gal6 that facilitate the removal of CHO specific alpha-2,3-sialylation.
- 3) Inactivation and/or downregulation of the enzyme SPPL3 that facilitate to increase glycosyltransferases half-life in the Golgi.
- 4) Inactivation and/or downregulation of the enzyme FUT8 that facilitate the removal of core-fucosylation.
- 5) An optional inactivation and/or downregulation of the enzyme B3GNT2 that may remove elongated antennas.
- 6) An optional inactivation and/or downregulation of the enzyme GLUL that may boost cell growth, and may be used for selection.
- 7) The insertion of a gene encoding Beta-galactoside alpha-2,6-sialyltransferase 1 (St6gal1), which gene direct a human type branching of sialic acids.
- With these modifications, it would be accomplished to shift in the glycosylation profile to the predominant bi-antennary form found in human plasma of recombinant produced serum glycoproteins, such as human serum proteins, such as human AAT, such as in CHO cells.
- A host cell with these modifications may then be modified by insertion of a gene expressing an exogenous human glycoprotein of interest, such as a therapeutic human protein, such as a human serum protein, such as Plasma protease C1 inhibitor (C1Inh), Antithrombin-III (ATIII) or Human alpha-1-antitrypsin (AAT).
- In some embodiments the mammalian cells used according to the present inventions is selected from the group consisting of a Chinese Hamster Ovarian (CHO) cells, such as CHO-K1; Baby Hamster Kidney (BHK) cell; COS cell; HEK293; NSO; SP2/0; YB2/0; HUVEC; HKB; PER-C6; or derivatives of any of these cells.
- In some embodiments the cell line according to the present invention is modified to express a gene expressing an exogenous human glycoprotein of interest, such as a human serum protein selected from any one human serpin of table 1:
-
TABLE 1 Serpin Alternative name(s) SERPINA1 Antitrypsin, Alpha-1-antitrypsin or α1-antitrypsin SERPINA2 Antitrypsin-related protein SERPINA3 Antichymotrypsin SERPINA4 Kallistatin (PI4) SERPINA5 Protein C inhibitor (PAI-3) SERPINA6 Corticosteroid-binding globulin SERPINA7 Thyroxine-binding globulin SERPINA8 Angiotensinogen SERPINA9 Centerin SERPINA10 Protein Z-dependent proteinase inhibitor SERPINA11 XP_170754.3 SERPINA12 Vaspin SERPINA13 XM_370772 SERPINB1 Monocyte neutrophil elastase inhibitor SERPINB2 Plasminogen activator inhibitor-2 (PAI2) SERPINB3 Squamous cell carcinoma antigen-1 SERPINB4 Squamous cell carcinoma antigen-2 SERPINB5 Maspin SERPINB6 Proteinase inhibitor-6 (PI6) SERPINB7 Megsin SERPINB8 Cytoplasmic antiproteinase 8 (PI8) SERPINB9 Cytoplasmic antiproteinase 9 (PI9) SERPINB10 Bomapin (PI10) SERPINB11 Epipin SERPINB12 Yukopin SERPINB13 Headpin (PI13) SERPINC1 Antithrombin SERPIND1 Heparin cofactor II SERPINE1 Plasminogen activator inhibitor I (PAI1) SERPINE2 Protease nexin I (PI7) SERPINE3 Hs.512272 SERPINF1 Pigment epithelium derived factor SERPINF2 Alpha-2-antiplasmin SERPING1 C1 inhibitor SERPINH1 47 kDa heat-shock protein SERPINI1 Neuroserpin (PI12) SERPINI2 Myoepithelium-derived serine proteinase inhibitor (PI14) - In particular the present inventors aimed to produce rhA1AT and rhC1INH in CHO-S with N-glycan profiles similar to pIAlAT and pIC1INH. First, the heterogeneous N-glycan profile of CHO-S WT cells was changed to more homogeneous profiles in bespoke cell lines with predominant A2G2 N-glycan structures. Disrupting nine N-glycosylation-related genes increased the A2G2 proportion on total secreted protein from 3.5% in CHO-S WT-derived cells to ˜80% in 10×KO cell lines. This supports the strategy to decrease N-glycan branching and alpha-2,3-sialylation by disrupting MGAT4A, MGAT4B, MGAT5, ST3GAL3, ST3GAL4 and ST3GAL6. The impact of gene disruptions on cell culture performance was assessed in batch cultures. Furthermore, the monoclonal cell lines with disruption in ten gene targets showed enhanced growth characteristics compared to CHO-S WT cells. This included a boosted cell growth in the GLUL-lacking 10×KO cell lines in L-glutamine-supplemented medium.
- In contrast to the production platforms previously described, rhAlAT and rhC1INH produced in the 10×KO cell lines described herein are not only exceeding sialylation levels of pIAlAT and pIC1INH but also reveal human-like alpha-2,6-sialylation instead of alpha-2,3-sialylation. The increased sialylation of rhAlAT had no impact on in vitro activity.
- The present inventors describes a strategy to successfully engineer the heterogeneous N-glycosylation profile of in particular CHO-S WT cells towards the specific A2G2S2 N-glycan structure with the purpose of producing serpins, such as rhA1AT and rhC1INH with N-glycan profiles similar to human plasma-derived products. Thus, the present invention shows the promise and potential of replacing cost-intensive and possibly unsafe plasma-derived augmentation therapy for AATD and C1INH-HAE patients by CHO- produced rhAlAT and rhC1INH. This strategy is in compliance with the Medical and Scientific Advisory Council (MASAC) recommendation of replacing plasma-derived products with recombinant products for treatment of diseases.
- Alpha-1-antitrypsin (A1AT or AAT) refers to the protein identified as UniProtKB-P01009 (A1AT_HUMAN).
- Plasma protease Cl inhibitor (ClInh) refers to the protein identified as UniProtKB-P05155 (IC1_HUMAN)
- Antithrombin-III (ATIII) refers to the protein identified as UniProtKB-P01008 (ANT3_HUMAN)
- The term “inactivated and/or downregulated” refers to a modification of a mammalian host cell, wherein some specific genes are either knocked out, downregulated, or completely or partially inactivated in any other way, such as by miRNA post translational silencing. Preferably this inactivation is a complete inactivation with no measurable sign of expression of this particular gene being inactivated. Suitable techniques to silence/knockout are very well described in the art and known to the person skilled in the art, e.g. as described in WO2015092737. In one specific embodiment, “inactivated and/or downregulated” refers to a gene knockout of the relevant gene.
- The term “MGAT4A” as used herein refers to the gene encoding Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isozyme A. This gene may also be referred to as
-
- UDP-N-Acetylglucosamine: Alpha-1,3-D-Mannoside Beta-1,4-N-Acetylglucosaminyltransferase Iva;
- Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isoenzyme A;
- N-Glycosyl-Oligosaccharide-Glycoprotein N-Acetylglucosaminyltransferase Iva;
- N-Acetylglucosaminyltransferase Iva;
- GlcNAc-T Iva;
- EC 2.4.1.145;
- GNT-
IVA 3; - UDP-N-Acetylglucosamine:
Alpha 1,3-D-Mannoside Beta 1,4-N-Acetylglucosaminyltransferase; - Alpha-1,3-Mannosyl-Glycoprotein 4-Beta-N-Acetylglucosaminyltransferase A;
- Alpha-1,3-Mannosyl-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase;
- UDP-GIcNAc:A-1,3-D-Mannoside B-1,4-Acetylglucosaminyltransferase IV;
- GNT-IV; and
- GnT-4a.
- The term “MGAT4B” as used herein refers to the gene encoding Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isozyme B. This gene may also be referred to as
-
- UDP-N-Acetylglucosamine: Alpha-1,3-D-Mannoside Beta-1,4-N-Acetylglucosaminyltransferase IVb;
- Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isoenzyme B;
- N-Glycosyl-Oligosaccharide-Glycoprotein N-Acetylglucosaminyltransferase IVb;
- N-Acetylglucosaminyltransferase IVb;
- GlcNAc-T IVb;
- EC 2.4.1.145;
- GNT-
IVB 3; - UDP-N-Acetylglucosamine: Alpha-1,3-D-Mannoside Beta-1,4-N-Acetylglucosaminyltransferase IV;
- Alpha-1,3-Mannosyl-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase;
- Alpha-1,3-Mannosyl-Glycoprotein 4-Beta-N-Acetylglucosaminyltransferase B;
- Aminyltransferase; and
- GNT-IV.
- The term “MGATS” as used herein refers to the gene encoding Mannosyl (Alpha-1,6-)-Glycoprotein Beta-1,6-N-Acetyl-Glucosaminyltransferase. This gene may also be referred to as
-
- Alpha-Mannoside Beta-1,6-N-Acetylglucosaminyltransferase;
- Mannoside Acetylglucosaminyltransferase;
- N-Acetylglucosaminyl-Transferase V;
- EC 2.4.1.155;
- GlcNAc-T V;
- GNT-V;
- Alpha-1,6-Mannosylglycoprotein 6-Beta-N-Acetylglucosaminyltransferase A;
- GNT-VA; and
- GGNTS.
- The term “ST3GAL3” as used herein refers to the gene encoding ST3 Beta-Galactoside Alpha-2,3-
Sialyltransferase 3. This gene may also be referred to as ST3Gal III; -
- Sialyltransferase 6 (N-
Acetyllacosaminide Alpha 2,3-Sialyltransferase); -
Alpha 2,3-ST; - ST3GalIII;
- SIAT6;
- ST3N;
- CMP-N-Acetylneuraminate-Beta-1,4-Galactoside Alpha-2,3-Sialyltransferase;
- Gal Beta-1,3(4) GlcNAc Alpha-2,3 Sialyltransferase;
- Gal Beta-1,3(4)GIcNAc Alpha-2,3 Sialyltransferase;
- N-Acetyllactosaminide Alpha-2,3-Sialyltransferase;
- Beta-Galactoside Alpha-2,3-Sialyltransferase;
-
Alpha 2,3-Sialyltransferase III; - Alpha-2,3-Sialyltransferase II;
-
Sialyltransferase 6; - EC 2.4.99.6;
- ST3GALII;
- EIEE15; and
- MRT12.
- Sialyltransferase 6 (N-
- The term “ST3GAL4” as used herein refers to the gene encoding ST3 Beta-Galactoside Alpha-2,3-
Sialyltransferase 4. This gene may also be referred to as Sialyltransferase 4C (Beta-Galactosidase Alpha-2,3-Sialytransferase); -
- Gal-Beta-1,4-GalNAc-Alpha-2,3-Sialyltransferase;
- Beta-Galactoside Alpha-2,3-
Sialyltransferase 4; -
Alpha 2,3-Sialyltransferase IV; -
Alpha 2,3-ST 4; - Gal-NAc6S;
- ST3GalA.2;
- ST3Gal IV;
- ST3GalIV;
- NANTA3;
- SIAT4C;
- CGS23;
- ST-4;
- STZ;
- CMP-N-Acetylneuraminate-Beta-Galactosamide-Alpha-2,3-Sialyltransferase;
- Sialyltransferase 4C (Beta-Galactoside Alpha-2,3-Sialytransferase);
- Alpha-3-N-Acetylneuraminyltransferase;
- Sialyltransferase 4C;
- EC 2.4.99.9;
- EC 2.4.99.-;
- EC 2.4.99;
- SIAT4-C;
- SIAT4;
- SAT-3; and
- The term “ST3GAL6” as used herein refers to the gene encoding ST3 Beta-Galactoside Alpha-10 2,3-
Sialyltransferase 6. This gene may also be referred to as CMP-NeuAc:Beta-Galactoside Alpha-2,3-Sialyltransferase VI; -
- Sialyltransferase 10 (Alpha-2,3-Sialyltransferase VI);
- ST3GALVI;
- SIAT10;
-
Type 2 Lactosamine Alpha-2,3-Sialyltransferase;
- Alpha2,3-Sialyltransferase ST3Gal VI;
-
- Sialyltransferase;
- EC 2.4.99.9;
- EC 2.4.99.-;
- ST3Gal VI; and
- EC 2.4.99.
- The term “B3GNT2” as used herein refers to the gene encoding UDP-GlcNAc:BetaGal Beta-1,3-N-
Acetylglucosaminyltransferase 2. This gene may also be referred to as UDP-GIcNAc:BetaGal Beta-1,3-N-Acetylglucosaminyltransferase; -
- Beta3Gn-T1;
- Beta3Gn-T2;
- B3GNT1;
- BGnT-2;
- UDP-Galactose:Beta-N-Acetylglucosamine Beta-1,3-
Galactosyltransferase 7; - N-Acetyllactosaminide Beta-1,3-N-Acetylglucosaminyltransferase;
- UDP-Gal:Beta-GlcNAc Beta-1,3-
Galactosyltransferase 7; - Beta-1,3-N-Acetylglucosaminyltransferase BGnT-1;
- Beta-1,3-N-Acetylglucosaminyltransferase BGnT-2;
- Beta-1,3-N-
Acetylglucosaminyltransferase 1; - Beta-1,3-N-
Acetylglucosaminyltransferase 2; - Beta-1,3-
Galactosyltransferase 7; - Beta-1,3-
GalTase 7; - Beta-1,3-Gn-T1;
- Beta-1,3-Gn-T2;
- Beta-3-Gx-T7;
- EC 2.4.1.149;
- Beta3Gal-T7;
- Beta3Ga1T7;
- BETA3GNT;
- B3Gal-T7;
- 3-Gn-T1;
- 3-Gn-T2;
- B3GN-T2;
- B3GNT-2;
- B3GALT7;
- Beta-1;
- BGnT-1;
- B3GNT; and
- BGNT2.
- The term “GLUL” as used herein refers to the gene encoding glutamate-ammonia ligase also referred to as:
-
- Glutamate-Ammonia Ligase;
- Glutamate Decarboxylase;
-
- Glutamine Synthetase;
- EC 6.3.1.2;
- GLNS;
- GS;
- Glutamate-Ammonia Ligase (Glutamine Synthase);
- Cell Proliferation-Inducing Protein 59;
- Proliferation-Inducing Protein 43;
- Glutamate-Ammonia Ligase;
- Glutamine Synthase;
- EC 4.1.1.15;
-
- PIG43; and
- PIG59.
- The term “SPPL3” as used herein refers to the gene encoding Signal Peptide Peptidase Like 3. This gene may also be referred to as
-
- Presenilin-
Like Protein 4; -
Intramembrane Protease 2; -
Presenilin Homologous Protein 1; - SPP-Like 3;
- IMP2;
- PSH1;
- PSL4;
- Signal Peptide Peptidase-
Like 3; - EC 3.4.23.-;
- MDHV1887;
- PRO4332; and
- IMP-2.
- Presenilin-
- The term “FUT8” as used herein refers to the
gene encoding Fucosyltransferase 8. This gene may also be referred to as -
- GDP-L-Fuc:N-Acetyl-Beta-D-Glucosaminide Alpha1,6-Fucosyltransferase;
- Fucosyltransferase 8 (Alpha (1,6) Fucosyltransferase);
- GDP-Fucose--Glycoprotein Fucosyltransferase;
- Glycoprotein 6-Alpha-L-Fucosyltransferase;
- Alpha1-6FucT;
- EC 2.4.1.68 4;
- Alpha (1,6) Fucosyltransferase;
- Alpha-(1,6)-Fucosyltransferase
- The term “ST6Gal1” as used herein refers to the gene encoding ST6 Beta-Galactoside Alpha-2,6-
Sialyltransferase 1. This gene may also be referred to as ST6Gal I; -
- CMP-N-Acetylneuraminate-Beta-Galactosamide-Alpha-2,6-Sialyltransferase 1:
- ST6 N-Acetylgalactosaminide Alpha-2,6-
Sialyltransferase 1; - ST6 Beta-Galactosamide Alpha-2,6-
Sialyltranferase 1; - B-Cell Antigen CD75;
-
Alpha 2,6-ST 1; - EC 2.4.99.1;
- ST6GalI;
- SIAT1;
- CMP-N-Acetylneuraminate Beta-Galactosamide Alpha-2,6-Sialyltransferase;
- Sialyltransferase 1 (Beta-Galactoside Alpha-2,6-Sialyltransferase);
- Sialyltransferase 1 (Beta-Galactoside Alpha-2,6-Sialytransferase);
- Beta-Galactoside Alpha-2,6-
Sialyltransferase 1; -
Sialyltransferase 1; and - ST6N.
- As detailed above in a first aspect the present invention relates to a recombinant mammalian cell line having a) one or more of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 inactivated and/or downregulated; and b) optionally a gene encoding Beta-galactoside alpha-2,6-
sialyltransferase 1 inserted. - In some embodiments of the mammalian cell according to present invention the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 are inactivated and/or downregulated; and the gene encoding ST6Gal1 is inserted.
- In some embodiments the mammalian cell according to present invention has the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal4, St3Gal6, and FUT8 inactivated and/or downregulated.
- In some embodiments the mammalian cell according to present invention has the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal4, St3Gal6, SPPL3, and FUT8 inactivated and/or downregulated.
- In some embodiments of the mammalian cell according to present invention the endogenous gene B3GNT2 is present.
- In some embodiments the mammalian cell according to present invention further has the endogenous B3GNT2 is inactivated and/or downregulated. It is to be understood that this may be in addition to any combination of other genes being inactivated and/or downregulated.
- In some embodiments the mammalian cell according to present invention further has the endogenous GLUL is inactivated and/or downregulated. It is to be understood that this may be in addition to any combination of other genes being inactivated and/or downregulated.
- In some embodiments the mammalian cell according to present invention is an in vitro
cell 25 line, such as any one selected from the group consisting of a Chinese Hamster Ovarian (CHO) cells, such as CHO-K1, CHO-S, DG44; Baby Hamster Kidney (BHK) cell; COS cell; HEK293; NSO; SP2/0; YB2/0; HUVEC; HKB; PER-C6; NSO; or derivatives of any of these cells. - In some embodiments the mammalian cell according to present invention has been further modified to express an exogenous human glycoprotein of interest, such as a therapeutic human protein. In some embodiments said exogenous human glycoprotein of interest is a human serum protein, such as a human serpin, such as human serpin selected from the list consisting of SERPINA1, SERPINA2, SERPINA3, SERPINA4, SERPINA5, SERPINA6, SERPINA7, SERPINA8, SERPINA9, SERPINA10, SERPINA11, SERPINA12, SERPINA13, SERPINB1, SERPINB2, SERPINB3, SERPINB4, SERPINB5, SERPINB6, SERPINB7, SERPINB8, SERPINB9, SERPINB10, SERPINB11, SERPINB12, SERPINB13, SERPINC1, SERPIND1, SERPINE1, SERPINE2, SERPINE3, SERPINF1, SERPINF2, SERPING1, SERPINH1, SERPINI1, and SERPINI2.
- In some embodiments the mammalian cell according to present invention is a cell line producing said glycoprotein of interest with a primary n-glycan structure that is a fully sialylated bi-antennary structure without core fucosylation, such as with more than 80%, such as 82%, such as 84%, such as 86%, such as 88%, such as 90% of the glycoproteins of interest produced being in with a fully sialylated bi-antennary structure without core fucosylation.
- In some embodiments the mammalian cell according to present invention has a glycan structure according to the structure A2G2S2 with the following pictorial representations:
-
- Such as according to the structure:
-
- In some embodiments the mammalian cell according to present invention has been further modified to express an exogenous human glycoprotein of interest, which exogenous human glycoprotein of interest is selected from Plasma protease C1 inhibitor (C1Inh) glycosylated at one or more positions selected from Asn3, Asn47, Asn59, Asn216, Asn231, Asn250, and Asn330; Antithrombin-III (ATIII) glycosylated at one or more positions selected from Asn96, Asn135, Asn155 and Asn192; and Human alpha-1-antitrypsin (AAT) glycosylated at one or more, such as two or three of the positions Asn46, Asn83, and Asn247.
- We knocked out 9 genes in the CHO-S cell line employing CRISPR/Cas9: FUT8, MGAT4a, MGAT4b, MGAT5, ST3GAL3, ST3GAL4, ST3GAL6, B3gnt2, Sppl3. Furthermore, we introduced the human gene ST6GAL1 to introduce human type branching of sialic acids. The human genes SERPING or SERPINA were then introduced in this host cell line to achieve expression of the human serum proteins Plasma protease Cl inhibitor (ClInh) or Human alpha-1-antitrypsin (AAT), respectively. With these modifications, it is accomplished to shift in the glycosylation profile to the predominant bi-antennary, non-core-fucosylated, and α2-6 linked sialic acid form found in human plasma of recombinant produced serum glycoproteins (
FIG. 3 ). IEF migration patterns are identical between AAT derived from plasma and the 15 glycoengineered cell line described here (FIG. 4 ). Activity of AAT is not affected (FIG. 5 ). - Plasmids 2632 (GFP_2A_Cas9) and 5920 (FUT8_681494) are described in Gray, L. M., Lee, 3. S., Gerling, S., Kallehauge, T. B., Hansen, A, H., Kol, S., Lee, G. M., Pedersen, L. E. and Kildegaard, H. F. (2015), One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnology Journal, 10: 1446-1456. doi10.1002/biot.201500027.
- Plasmids 2928 (MGAT4A_411545), 2933 (MGAT4B_1280368), 2937 (MGAT5_327084), 2940 (ST3GAL4_964386), 2943 (ST3GAL6_1812502), 4408 (B3gnt2 NW 003613880.1_1273293), 4412 (St3_gal3_NW_003613906.1_244730) and 4424 (Sppl3_NW_003613978.1_213040) were constructed as described in Ronda, C., Pedersen, L. E, Hansen, H. G., Kallehauge, T. B, et al., Accelerating genome editing in CHO cells using CRISPR/Cas9 and CRISPy, a web-based target finding tool, Biotechnol. Bioeng. 2014, 111, 1604-4616 with the following modification: sgRNA plasmid sgRNA1_C described in Ronda et al was used as template in the PCR reaction to generate the backbone of gRNA plasmids.
- St6Gal1 vector map is shown in
FIG. 6 . - SerpinA vector map is shown in
FIG. 7 . - SerpinG vector map is shown in
FIG. 8 . - SerpinC1 vector map is shown in
FIG. 9 . - We knocked out 10 genes in the CHO-S cell line employing CRISPR/Cas9: FUT8, MGAT4a, MGAT4b, MGAT5, ST3GAL3, ST3GAL4, ST3GAL6, B3gnt2, Sppl3 and GLUL. We have constructed plasmids harbouring both the human ST6GAL1, and SERPING or SERPINA genes to simultaneously introduce human type branching of sialic acids and achieve expression of Plasma protease C1 inhibitor (ClInh), or Human alpha-1-antitrypsin (AAT), respectively.
- Combined St6Gal1/SerpinA vector map is shown in
FIG. 10 . - Combined St6Gall/SerpinG vector map is shown in
FIG. 11 . - N-glycan analysis was performed with GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, Mass.) according to the manufacturer's instruction. In this
case 12 μl of 10×concentrated (MWCO filtered, Amicon Ultra-15, Merck, Darmstadt, Germany) secretome or purified protein sample were used for each. Labeled N-Glycans were analyzed by a LC-MS system using aThermo Ultimate 3000 HPLC with fluorescence detector coupled on-line to a Thermo Velos Pro Iontrap MS.Separation gradient 30% to 43% buffer and MS was run in positive mode. - sgRNA, GFP_2A_Cas9 and A1AT/C1INH_St6gal1_GLUL Plasmid Design.
- GFP_2A_Cas9 and single guide RNA (sgRNA) plasmids were constructed as previously described (Gray, L.M. et al., One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnol. J. 2015, 10, 1446-1456). The sgRNA target design for MGAT4A, MGAT4B, MGAT5, ST3GAL3, ST3GAL4, ST3GAL6, B3GNT2, FUT8, SPPL3 and GLUL was performed using “CRISPy” (Ronda, C. et al., Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool. Biotechnol. Bioeng. 2014, 111, 1604-1616). The target sites for the mentioned genes and the oligos for sgRNA cloning are listed in Table 2 and Table 3, respectively.
-
TABLE 2 sgRNA target sequences. The bases in bold mark the PAM site Gene name of target hypothesized KO effect Target sequence (5′-> 3′) MGAT4A decreased branching GTCTACATTCGTCACTGTCGGGG (SEQ ID NO: 1) MGAT4B decreased branching GCTTCAGTCGCGGATCCTCTGGG (SEQ ID NO: 2) MGAT5 decreased branching GGATGGCTACCCCCACTGCGAGG (SEQ ID NO: 3) ST3GAL3 decreased sialylation GATCCTAGCCCACTTTCGAAAGG (SEQ ID NO: 4) ST3GAL4 decreased sialylation GTGTCGTCGTTGTGTTGTGGTGG (SEQ ID NO: 5) ST3GAL6 decreased sialylation GGAGTTGTGATCATTGTGAGCGG (SEQ ID NO: 6) B3GNT2 decreased elongation GTTGGGCAAGACGCCCCCCGAGG (SEQ ID NO: 7) FUT8 no core-fucosylation GTCAGACGCACTGACAAAGTGGG (SEQ ID NO: 8) SPPL3 hyper-glycosylation AGAGAGACGGACGCTCCAATAGG (SEQ ID NO: 9) GLUL* Gln-dependent growth TCCCAAATCAGCAAACAGACTGG (SEQ ID NO: 10) *the GLUL sgRNA efficiency during KO-generation of the presented sequence was very low compared to other target sgRNAs and we recommend the usage of a different design. -
TABLE 3 Oligos for sgRNA expression vector cloning. Oligo Name Oligo sequence (5′ −> 3′) gRNA_MGAT4A_411545_fwd GGAAAGGACGAAACACCGTCTACA TTCGTCACTGTCGGTTTTAGAGCT AGAAAT (SEQ ID NO: 11) gRNA_MGAT4A_411545_rev CTAAAACGACAGTGACGAATGTAG ACCGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 12) gRNA_MGAT4B_1280368_fwd GGAAAGGACGAAACACCGCTTCAG TCGCGGATCCTCTGTTTTAGAGCT AGAAAT (SEQ ID NO: 13) gRNA_MGAT4B_1280368_rev CTAAAACAGAGGATCCGCGACTGA AGCGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 14) gRNA_MGAT5_327084_fwd GGAAAGGACGAAACACCGGATGGC TACCCCCACTGCGGTTTTAGAGCT AGAAAT (SEQ ID NO: 15) gRNA_MGAT5_327084_rev CTAAAACCGCAGTGGGGGTAGCCA TCCGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 16) gRNA_ST3GAL3_244730_fwd GGAAAGGACGAAACACCGATCCTA GCCCACTTTCGAAGTTTTAGAGCT AGAAAT (SEQ ID NO: 17) gRNA_ST3GAL3_244730_rev CTAAAACTTCGAAAGTGGGCTAGG ATCGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 18) gRNA_ST3GAL4_964386_fwd GGAAAGGACGAAACACCGTGTCGT CGTTGTGTTGTGGGTTTTAGAGCT AGAAAT (SEQ ID NO: 19) gRNA_ST3GAL4_964386_rev CTAAAACCACAACACAACGACGAC ACCGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 20 gRNA_ST3GAL6_1812502_fwd GGAAAGGACGAAACACCGGAGTTG TGATCATTGTGAGGTTTTAGAGCT AGAAAT (SEQ ID NO: 21) gRNA_ST3GAL6_1812502_rev CTAAAACCTCACAATGATCACAAC TCCGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 22) gRNA_B3GNT2_1273293_fwd GGAAAGGACGAAACACCGTTGGGC AAGACGCCCCCCGGTTTTAGAGCT AGAAAT (SEQ ID NO: 23) gRNA_B3GNT2_1273293_rev CTAAAACCGGGGGGCGTCTTGCCC AACGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 24) gRNA_FUT8_681494_fwd GGAAAGGACGAAACACCGTCAGAC GCACTGACAAAGTGTTTTAGAGCT AGAAAT (SEQ ID NO: 25 gRNA_FUT8_681494_rev CTAAAACACTTTGTCAGTGCGTCT GACGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 26) gRNA_SPPL3_213040_fwd GGAAAGGACGAAACACCAGAGAGA CGGACGCTCCAATGTTTTAGAGCT AGAAAT (SEQ ID NO: 27) gRNA_SPPL3_213040_rev CTAAAACATTGGAGCGTCCGTCTC TCTGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 28 gRNA_GLUL_941540_fwd GGAAAGGACGAAACACCGGCCCAG GGAAGCCATCGGAGTTTTAGAGCT AGAAAT (SEQ ID NO: 29) gRNA_GLUL_941540_rev CTAAAACTCCGATGGCTTCCCTGG GCCGGTGTTTCGTCCTTTCCACAA GATAT (SEQ ID NO: 30) - Plasmids for co-expression of A1AT/C1INH and St6gal1 were constructed with uracil-specific excision reagent cloning method as previously described (Pristovšek, N. et al., Using Titer and Titer Normalized to Confluence Are Complementary Strategies for Obtaining Chinese Hamster Ovary Cell Lines with High Volumetric Productivity of Etanercept. Biotechnol. J. 2018, 13; and Lund, A. M. et al., A Versatile System for USER Cloning-Based Assembly of Expression Vectors for Mammalian Cell Engineering. PLOS ONE 2014, 9(5): e96693). The DNA sequences of the plasmids are listed in
FIG. 17 . - Cell Cultivation and Transfection for Genome Editing.
- CHO-S suspension cells were incubated in a humidified incubator at 120 rpm, 37° C., 5% CO2, passaged to 2-3×105 cells/mL every 2-3 days and transfected in 6-well plates (BD Biosciences, San Jose, Calif.) as described previously (Gray, L. M. et al., One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnol. J. 2015, 10, 1446-1456). The GFP_2A_Cas9/sgRNA plasmid ratios for each transfection was 1:1 of which the plasmid load of sgRNA was divided equally by the amount of different sgRNAs used per transfection (Table 5). To measure FACS sorting efficiency, pmaxGFP® vector (Lonza, Basel, Switzerland) transfection was performed as well. Cells were harvested for fluorescence-activated cell sorting (FACS) 48 h post transfection.
-
TABLE 5 Indels generated in ten targeted genes by CRISPR/Cas9 multiplexing. Multiplexing round 1 2 3 4 Gene MGAT4A MGAT4B MGAT5 ST3GAL4 ST3GAL6 ST3GAL3 B3GNT2 GLUL SPPL3 FUT8 10× KO +2 −1 +1 −5/+1 +1 +1/+2 −1 −13/−10/−2 +1 +1 clone A 10× KO +2 −1 +1 −5/+1 +1 +1/+2 −1 −13/−10/−2 +1 −7/−1 clone B - Single Cell Cloning of Genome Edited Cells Using FACS.
- Before FACS, cells were filtered through a 40 μm cell strainer into a FACS-compatible tube.
- Single fluorescent-positive (GFP) cells were sorted into 384-well plates (Corning, New York, N.Y.) containing 30 μL CD CHO medium supplemented with 8 mM L-glutamine, 1.5% HEPES buffer and 1% Antibiotic-Antimycotic (Gibco, Waltham, Mass.) per well as described previously (Hansen, H. G. et al, Case study on human alpha1 -antitrypsin: Recombinant protein titers obtained by commercial ELISA kits are inaccurate. Biotechnol. J. 2016, 11, 1648-1656). For cell sorting, fluorescent-positive cell populations were gated based on non-transfected WT CHO-S cells. Two weeks after cell sorting cell colonies were moved to 96-well flat-bottom plates (BD Biosciences) and expanded for deep sequencing analysis and batch cultivation.
- Deep Sequencing Analysis.
- Confluent colonies from 96-well flat-bottom replicate plates were harvested for genomic DNA extraction. DNA extraction was performed using QuickExtract DNA extraction solution (Epicentre, Illumina, Madison, Wis. according to the manufacturer's instruction. The library preparation was based on Illumina 16S Metagenomic Sequencing Library Preparation and deep sequencing was carried out on a MiSeq Benchtop Sequencer (Illumina, San Diego, Calif.). The protocol for amplifying the targeted genomic sequences, amplicon purification, adapter-PCR and following quality analysis was based on previously published work (Gray, L. M. et al., One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnol. J. 2015, 10, 1446-1456). PCR primers are presented in Table 6.
-
TABLE 6 Primer list for deep sequencing (MiSeq). The primers contain overhang sequences compatible with Illumina Nextera XT indexing (forward primeroverhang: TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAG (SEQ ID NO: 33), reverse primer overhang: GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAG(SEQ ID NO: 34)). primer name sequence (5′ −> 3′) MiSeq_MGAT4A_411545_fwd TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGGACAGACAGAAGGCA AATCTACG (SEQ ID NO: 35) MiSeq_MGAT4A_411545_rev GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGTTAACAGCTACACA GGAAGAGCA (SEQ ID NO: 36) MiSeq_MGAT4B_1280368_fwd TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGGGGATGGGGTGTATG GAGGT (SEQ ID NO: 37) MiSeq_MGAT4B_1280368_rev GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGTTGCAGACTGCTCT CCTTGG (SEQ ID NO: 38) MiSeq_MGAT5_327084_fwd TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGCATGAATCTCATGGT TTCCTTTGT (SEQ ID NO: 39) MiSeq_MGAT5_327084_rev GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGGCTTCAAGACTCAA CTCTTTCCC (SEQ ID NO: 40) MiSeq_ST3GAL3_244730_fwd TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGGGGAAACAGCATGGG CAAAC (SEQ ID NO: 41) MiSeq_ST3GAL3_244730_rev GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGACTGGAATGTGGAT GGTGGC (SEQ ID NO: 42) MiSeq_ST3GAL4_964386_fwd TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGACACCTGATGACCAC ATCGT (SEQ ID NO: 43) MiSeq_ST3GAL4_964386_rev GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGGCAGGGTCCACTTC TGGATT (SEQ ID NO: 44) MiSeq_ST3GAL6_1812502_fwd TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGTCACTGTCTTACTAC CCACAGGA (SEQ ID NO: 45) MiSeq_ST3GAL6_1812502_rev GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGTCCTTTCATTATAT TCAAGAGCCAC (SEQ ID NO: 46) MiSeq_B3GNT2_1273293_fwd TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGCTCACCCACCGGAGA AACAG (SEQ ID NO: 47) MiSeq_B3GNT2_1273293_rev GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGAGAAGGCAAGCAAT TCGGGA (SEQ ID NO: 48) MiSeq_FUT8_681494_fwd TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGTGCCCCCATGACTAG GGATA (SEQ ID NO: 49) MiSeq_FUT8_681494_rev GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGTCTGCGTTCGAGAA GCTGAAA (SEQ ID NO: 50) MiSeq_SPPL3_213040_fwd TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGCGTGGAGTAACTTAC CTGCTGT (SEQ ID NO: 51) MiSeq_SPPL3_213040_rev GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGAAGTGGTGAGTGTG TCCTGT (SEQ ID NO: 52) MiSeq_GLUL_941540_fwd2 TCGTCGGCAGCGTCAGATGTGTAT AAGAGACAGCAACCAGCACCCCTG GTT(SEQ ID NO: 53) MiSeq_GLUL_941540_rev2 GTCTCGTGGGCTCGGAGATGTGTA TAAGAGACAGCAGCTGCCAGTCTG TTTGC (SEQ ID NO: 54) - Transfection and expression in polyclonal cell lines by applying MSX-selection Cells were seeded in 250 mL Corning vent cap shake flasks (Sigma-Aldrich) as duplicates with cell densities ˜1×106 cells/mL in 60 mL CD CHO medium supplemented with 8 mM L-glutamine (Life Technologies) and transfected with 75 μg of A1AT-GLUL-St6gal plasmid or 75 μg of C1INH-GLUL-St6gal1 plasmid using FreeStyleTM MAX reagent together with OptiPRO
- SFM medium (Life Technologies) according to the manufacturer's recommendations. 1 μL/mL anti-clumping agent was added 24 h after transfection. pmaxGFP® vector (Lonza) transfection was performed to measure transfection efficiencies. Two days after transfection, cells were transferred into 60 mL CD CHO medium lacking L-glutamine (Life Technologies) and supplemented with 1 μL/mL anti-clumping agent and 0 μM, 10 μM, 30 μM or 50 μM MSX (EMD Millipore, Billerica, Mass.).
- Cell densities and viabilities were determined once per day using the NucleoCounter NC-250 Cell Counter (ChemoMetec). The cells were passaged in fresh selection medium every 2-3 days until viability and doubling time reached stable values. Polyclonal cell lines (pools) were seeded in duplicates at ˜1×106 cells/mL with corresponding MSX concentrations. Cell densities and viabilities were determined once per day and supernatants of the pools were harvested three days after seeding and pooled within duplicates for purification of rhAlAT and rhC1INH.
- Single Cell Cloning of Cells from Polyclonal Cell Pools Using FACS
- Non-stained single cells were sorted from pools as described above. For cell sorting, all viable cells were gated for sorting into 384-well plates with L-glutamine-free medium. Two weeks after cell sorting the clones were moved to 96-well flat-bottom plates (BD Biosciences) and expanded to shake flask format in CD CHO medium supplemented with 1pL/mL anti-clumping agent, 25 μM MSX and lacking L-glutamine.
- Screening cell pools and single cell clones for human-like a-2,6-sialic acid linkage formation with lectin staining.
- For lectin staining of cells, triplicates of 10,000 cells per sample were diluted in 200 pL of 0.22 μm pore size filtered CD CHO medium (Life Technologies) supplemented with 5 μg/mL Hoechst 33342 (Merck, Darmstadt, Germany) and 1 μg/mL Fluorescein isothiocyanate (FITC) labeled Sambucus nigra agglutinin (SNA) lectin (Biomol, Hamburg, Germany). After 60 min incubation in the dark at 37° C. and 5% CO2 the cells were washed with 200 μL CD CHO medium and then washed twice with 200 μL phosphate buffered saline (PBS) (300 g, 5 min, RT). The samples were resuspended in 200 ul PBS and transferred to 96-well plate for final centrifugation at 300 g for one minute. Percentage of FITC SNA positive cells was determined in a 96-well optical-bottom microplate (Greiner Bio-One, Frickenhausen, Germany) using a Celigo Imaging Cell Cytometer (Nexcelom Bioscience, Lawrence, Mass.). Cells were identified using the blue channel (Hoechst-positive cells), and the green channel (FITC SNA-positive cells) was used to detect cells with alpha-2,6-sialic acid linkage. A Hoechst/FITC SNA-stained CHO-S WT sample was gated to distinguish between FITC-positive and FITC-negative cells.
- Batch Cultivation: Cell Growth Analysis and N-glycosylation Profiling.
- For batch cultivation and N-glycan analysis, cells were seeded at 0.4×106 cells/mL in 250 mL Corning vent cap shake flasks (Sigma-Aldrich, St. Louis, Mich.) as duplicates in 60 mL CD CHO medium supplemented with 1 μL/mL anti-clumping agent (Life Technologies). CHO-S WT and non-producing parental 10×KO cell lines were additionally supplemented with 8 mM L-glutamine. rhA1AT/rhC1INH producing clones were cultivated in L-glutamine-free medium at all times and passaged in medium containing 25 μM MSX until the batch cultivation was initiated. Cell densities and viabilities were determined once per day using the NucleoCounter NC-250 Cell Counter (ChemoMetec) until the viability was <70%, at which point the culture was terminated. Supernatant samples with total secreted protein (secretome) from CHO-S WT and parental, non-producing 10×KO cell lines were taken five days after seeding and pooled within biological replicates. The volume for secretome samples was calculated to harbor 20×106 cells. For all shake flasks, additional supernatant samples were taken by centrifuging 1 mL of cell suspension for 5 minutes at 1000 g and storage of supernatant at −80° C. until further analysis.
- rhA1AT and rhC1INH Purification
- rhA1AT and rhC1INH were purified using CaptureSelect affinity resins (Thermo Fisher Scientific) according to the manufacturer's instructions. rhA1AT was further purified by size exclusion chromatography on a Superdex 200
increase 10/300 GL column (GE Healthcare) equilibrated in PBS. - Titer Assessment of rhA1AT/rhC1INH Producing Clones
- rhA1AT and rhC1INH titers were determined using biolayer interferometry on an Octet RED96 (Pall, Menlo Park, Calif., USA) as described previously for A1AT (Noh, S. M. et al., Reduction of ammonia and lactate through the coupling of glutamine synthetase selection and downregulation of lactate dehydrogenase-A in CHO cells. Appl. Microbiol. Biotechnol. 2017, 101, 1035-1045). After hydration in PBS, streptavidin biosensors (18-5021, Fortebio, Pall) were functionalized with CaptureSelect biotin anti-A1AT conjugate or CaptureSelect biotin anti-C1INH conjugate (Thermo Fisher Scientific) at 5 μg/mL in PBS, and blocked in PBS containing 1 μg/mL biocytin (600 and 300 s incubation steps, respectively). Standards were prepared in spent CHO-S medium using plasma-derived A1AT (Athens Research & Technology) at 100, 50, 25, 12.5, 6.3, 3.1 and 1.6 μg/mL or C1INH (R&D systems) at 40, 20, 10, 5, 2.5, 1.25 and 0.625 μg/mL. Samples and standards were diluted two-fold and contained 0.1% BSA w/v, 0.1% tween-20 v/v, and 500 mM NaCl. When needed, samples were further diluted to fall within the range of the standard dilution series. After equilibration in spent CHO-S medium (120 s), samples and standards were measured for 300 s with a shaking speed of 1000 rpm at 30° C. Regeneration was performed with 50 mM TRIS, 2 M MgCl2, pH 7.5. Assays were performed in 96-well black microplates (Greiner Bio-One, Kremsmünster, Austria). Octet System Data Analysis 7.1 software was used to calculate binding rates and absolute A1AT and C1INH concentrations.
- SDS-PAGE, Isoelectric Focusing and PNGase Treatment
- SDS-PAGE was performed on Novex 4-12% Tris-Glycine mini gels and isoelectric focusing (IEF) was performed on Novex pH 3-10 IEF gels (Thermo Fisher Scientific) as per the manufacturer's instructions. Deglycosylation with PNGase F was performed according to the manufacturer's instructions (New England Biolabs, Ipswich, Mass.).
- Activity Sssays
- A1AT inhibitory activity was determined using the EnzChek Elastase Assay Kit (Molecular
- Probes, Eugene, Oreg.) according to the manufacturer's instructions. In short, A1AT (8.0, 4.0, 2.0, 1.0, 0.5, 0.25, 0.13, and 0.06 μM) was incubated with purified active porcine pancreatic elastase and fluorescently labelled substrate (DQ-elastin). Measurement of fluorescence was performed after 45 min at room temperature (Excitation: 485 nm, slit width 9.0 nm; Emission: 530 nm, slit width 13.5 nm).
- C1INH inhibitory activity was determined using the Technochrom C1INH Assay Kit (TechnoClone, Vienna, Austria). In short, plasma containing C1INH activity (120%, 60%, 30%) and samples (˜0.25 μM) were incubated with substrate-buffer mixture for 3 min at room temperature, after which 50% acetic acid was added. Extinction was measured at 405 nm.
- N-Glycan Analysis
- N-glycans were derivatized with GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, Mass.) according to the manufacturer's instruction. Briefly; 12 μg purified protein or 12 μl of 10×concentrated (Amicon Ultra-15, Merck) secretome sample were used for each sample. Labeled N-Glycans were analyzed by LC-MS as described previously (Gray, L. M. et al., One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. Biotechnol. J. 2015, 10, 1446-1456) Separation gradient from 30% to 43% 50 mM ammonium formate buffer and MS were run in positive mode. Amount of N-Glycan was measured by integrating the peaks with Thermo Xcalibur software (Thermo Fisher Scientific, Waltham, Mass.) giving the normalized, relative amount of the glycans.
- Results
- Growth Profile and N-glycan Profile of
Clonal 10×KO cell lines - The aim of our study was to produce rhAlAT and rhC1INH in CHO cells with N-glycan profiles similar to human pIAlAT and pIC1INH. Our approach was to engineer the heterogeneous N-glycan profile of CHO-S WT cells towards a homogeneous A2G2S2 N-glycan structure, which is the predominant N-glycan on plA1AT/plC1INH. To this end, we generated out-of-frame insertions or deletions (indels) in eight glycosyltransferases (MGAT4A, MGAT4B, MGAT5, ST3GAL3, ST3GAL4, ST3GAL6, B3GNT2, FUT8) as well as in the genes SPPL3 and GLUL (Table 5) over four successive rounds of multiplexed CRISPR/Cas9 gene editing. Two clones with indels in the targeted genes were subjected to growth analysis and N-glycan profiling.
- Two clones (10×KO A and 10×KO B) with out-of-frame indels in all ten gene targets were obtained and both showed a pronounced increase in batch culture longevity when compared to the parental CHO-S WT cell line (
FIG. 12A ). - CHO-S WT reached maximal viable cell density of —6×106 cells/mL on day five and cell viability declined rapidly to <50% on
day 6. In contrast, the 10×KO A and 10x KO B clones had cell viabilities >75% untilday 10 of the batch cultivation and reached higher maximal viable cell density than CHO-S WT. - N-glycan analysis of the CHO-S WT secretome resulted in more than 25 N-glycan structures (
FIG. 12B ) where the A2G2S2 structure with alpha-2,6-linked sialic acids, predominantly found on pIAlAT and pIC1INH, was not detected. The majority of CHO-S WT N-glycans contained core-fucosylation. The N-glycans produced by CHO-S WT cells appear diverse and comprise high-mannose structures as well as non-galactosylated, fully and partially sialylated di-, tri- and tetra-antennary structures (all with alpha-2,3-linked sialic acids). A2FG2S2 was found as the main N-glycan on total secreted proteins of CHO-S WT. In contrast, the N-glycan profiles of 10×KO A and 10×KO B are more homogeneous (FIG. 12B ) with all structures lacking core-fucosylation. In addition, only relatively small amounts of CHO-specific alpha-2,3-linked sialylation were present. - After disruption of the targeted genes, the proportion of A2G2 within N-glycan structures of total secreted proteins was increased from 3.5% (CHO-S WT) to 79% in both 10×KO clones (
FIG. 12C ). We concluded that the 10×KO A and B clones were suitable host cell lines in our effort to generate humanized N-glycans. - Introducing Human-Like Sialylation in 10×KO Cell Lines
- On the basis of A2G2 secretome N-glycan structures of
clone 10×KO B, we aimed to develop clonal cell lines expressing St6gall and rhC1INH or St6gall and rhAlAT. We envisioned that such cell lines are capable to produce rhA1AT or rhC1INH with predominant A2G2S2 N-glycan structures as found on pIA1AT and pIC1INH. The functional GLUL-KO selection system was confirmed by MSX-dosage dependent recovery times of cell viabilities from transfected cell pools. Passaging of the different transfection pools was performed until viability and doubling times were stable. We then conducted FACS-based single cell cloning with the 50 μM MSX-selected cells. During the expansion of the generated clones, only clones exhibiting predominant FITC-SNA staining and detectable levels of rhA1AT/rhC1INH in supernatants on coomassie-stained SDS-PAGE gels were selected. Based on these criteria, two rhA1AT (A1-1 and A1-2) and two rhC1INH (C1-1 and C1-2) producing clones were selected for further characterization. - SNA lectins are reported to bind predominantly to sialic acids of N-glycans linked to the galactose residue in a human-like alpha-2,6-sialylation. Analyzing FITC-SNA-stained CHO-S WT, we found relatively low levels of alpha-2,6-sialylation (
FIG. 13A ). To determine the proportion of cells with human-like sialylation, FITC-SNA stained CHO-S WT samples were used to gate between FITC-positive and FITC-negative cells. Within the two 50 μM MSX-selected polyclonal cell lines, <30% of the cells were found to comprise alpha-2,6-linked sialic acids on N-glycans of cell surface proteins (FIG. 13B ). In comparison, 82-90% of the cells in the populations of the selected four clones (A1-1, A1-2, C1-1 and C1-2) had the desired alpha-2,6-linked sialic acids on their N-glycans. - SDS-PAGE gel analysis revealed that purified rhAlAT and rhCiINH produced in the four clones seem to have hydrodynamic volumes (molecular weight) similar to pIAlAT and pIC1INH without detectable impurities as seen in pIC1INH (
FIG. 15A ). rhAlAT and rhC1INH produced in CHO-S WT background did not co-migrate with pIAlAT and pIC1INH, respectively. However, after deglycosylation with PNGaseF, all recombinantly produced proteins aligned with corresponding bands of pIA1AT and pIC1INH with the exception of rhCiINH produced in a CHO-S WT background displayed an additional protein band at ˜65 kDa. - To further characterize the CHO-produced rhAlAT and rhC1INH, we performed IEF gel analysis (
FIG. 15B ). rhA1AT from clones A1-1 and A1-2 manifested in two bands with isoelectric points (pI) around pH 4.5 similar to pIAlAT. In contrast, rhAlAT produced in a CHO-S WT background displayed more than nine detectable isoforms with pI between pH 4-5. - IEF gel analysis of rhC1INH produced in a CHO-S WT background resulted in isoforms with pI ranging from pH ˜4-5. A high degree of heterogeneity was also found in purified rhClINH produced in clone C1-1. However, rhC1INH produced in clone C1-2 was less heterogeneous with pI at pH ˜3.5 similar to pIC1INH.
- In N-glycan analysis of purified rhA1AT and rhC1INH from CHO-S WT cells we detected a higher degree of heterogeneity compared to N-glycan structures on rhA1AT and rhC1INH from polyclonal 10×KO cell pools. The polyclonal cell lines revealed two predominant sugar structures on both proteins (A2G2 and A2G2S2 N-glycans), whereas we could not detect the A2G2S2 structure on products from CHO-S WT. Moreover, the amount of predominant N-glycan structures on rhAlAT and rhClINH was decreased from two (polyclonal pools) to one (monoclonal producers), identified as A2G2S2 N-glycan.
- All four 10×KO-derived monoclonal cell lines produced rhAlAT and rhClINH with higher proportion of A2G2S2 structures than pIA1AT and pIC1INH (
FIG. 15C ). The proportion of A2G2S2 in rhA1AT and rhC1INH was approximately 88-92% and 84%, respectively, and 82% for pIA1AT and 66% for pIC1INH. - Finally, we investigated the activity of purified rhA1AT and rhCl1NH. rhA1AT activity was determined by its inhibitory function of elastase activity (
FIG. 15D ). Similar to p1A1AT, a decrease in elastase activity was detected at A1AT concentrations >0.1 μM for rhA1AT from1clones A1-1 and A1-2. In addition, 50% of elastase inhibition was reached at —0.3 pM A1AT for pIAlAT as well as rhAlAT. In vitro activity of purified rhClINH produced by clones C1-1 and C1-2 was similar or higher compared to pIC1INH. - 1 engineered CHO Cell line with KO of the Sppl3 gene and CHO-S wt cells were both transiently transfected using chemical transfection with plasmids encoding either a Erythropoietin or C1inhibitor gene fused to a HPC4-affinity purification tag. The transfected cells were grown for 72 hours in CD CHO+8 mM L-gln using standard conditions as described previously, after which the supernatant was harvested, sterile filtered and stored at −80° C.
- For protein purification, the supernatants were thawed and purified by affinity chromatography using a 1-mL anti-protein C affinity column for EPO and Clinhibitor, and the fractions containing the EPO and Clinhibitor respectively were pooled.
- N-glycan analysis was performed on the purified samples, with GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, Mass.) according to the manufacturer's instruction. In this
case 12 μl of purified protein sample were used for each. Labeled N-Glycans were analyzed by a LC-MS system using aThermo Ultimate 3000 HPLC with fluorescence detector coupled on-line to a Thermo Velos Pro Iontrap MS.Separation gradient 30% to 43% buffer and MS was run in positive mode.
Claims (17)
1.-15. (canceled)
16. A recombinant human glycoprotein of interest produced according to a method comprising the steps of:
a) culturing a population of cells of a recombinant mammalian cell line in a suitable cell culture medium; and
b) harvesting said human protein of interest from the cell culture or cell culture medium,
wherein the recombinant mammalian cell line has
i) one or more of the endogenous genes Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, St3Gal6, SPPL3, and FUT8 inactivated and/or downregulated; and
ii) optionally a gene ST6Gal1 inserted,
and wherein the recombinant mammalian cell line has been further modified to express the recombinant human glycoprotein.
17. The recombinant human glycoprotein produced according to claim 16 , wherein the recombinant mammalian cell is a CHO-S cell line wherein the genes FUT8, MGAT4a, MGAT4b, MGAT5, ST3GAL3, ST3GAL4, ST3GAL6, B3GNT2 and SPPL3 are inactivated and/or downregulated and the human gene ST6GAL1 is inserted.
18. The recombinant human glycoprotein according to claim 17 , which is a human serum protein.
19. The recombinant human glycoprotein according to claim 18 , which is a human serpin.
20. The recombinant human glycoprotein according to claim 19 , wherein the human serpin is selected from the group consisting of SERPINA1 (AAT), SERPINA2, SERPINA3, SERPINA4, SERPINAS, SERPINA6, SERPINA7, SERPINA8, SERPINA9, SERPINA10, SERPINA11, SERPINA12, SERPINA13, SERPINB1, SERPINB2, SERPINB3, SERPINB4, SERPINB5, SERPINB6, SERPINB7, SERPINB8, SERPINB9, SERPINB10, SERPINB11, SERPINB12, SERPINB13, SERPINC1, SERPIND1, SERPINE1, SERPINE2, SERPINE3, SERPINF1, SERPINF2, SERPING1, SERPINH1, SERPINI1, and SERPINI2.
21. The recombinant human glycoprotein according to claim 17 , which has a primary n-glycan structure that is a fully sialylated bi-antennary structure without core fucosylation.
22. The recombinant human glycoprotein according to claim 21 , which glycan structure is according to the structure A2G2S2 with the following pictorial representation:
23. The recombinant human glycoprotein according to claim 22 , which a glycan structure is according to the following pictorial representation:
24. The recombinant human glycoprotein according to claim 22 , which is selected from the group consisting of
Plasma protease C1 inhibitor (C1Inh; SERPING1) glycosylated at one or more positions selected from Asn3, Asn47, Asn59, Asn216, Asn231, Asn250, and Asn330;
Antithrombin-III (ATIII; SERPINC1) glycosylated at one or more positions selected from Asn96, Asn135, Asn155 and Asn192; and
Human alpha-1-antitrypsin (AAT; SERPINA1) glycosylated at one or more, such as two or three of the positions Asn46, Asn83, and Asn247.
25. A preparation of a recombinant human glycoprotein, wherein more than 80% of the glycan structures of the recombinant human glycoprotein preparation is a fully sialylated bi-antennary structure without core fucosylation.
26. The preparation according to claim 25 , wherein the recombinant human glycoprotein is a human serum protein.
27. The preparation according to claim 26 , wherein the recombinant human glycoprotein is a human serpin.
28. The preparation according to claim 27 , wherein the human serpin is selected from the group consisting of SERPINA1 (AAT), SERPINA2, SERPINA3, SERPINA4, SERPINAS, SERPINA6, SERPINA7, SERPINA8, SERPINA9, SERPINA10, SERPINA11, SERPINA12, SERPINA13, SERPINB1, SERPINB2, SERPINB3, SERPINB4, SERPINBS, SERPINB6, SERPINB7, SERPINB8, SERPINB9, SERPINB10, SERPINB11, SERPINB12, SERPINB13, SERPINC1, SERPIND1, SERPINE1, SERPINE2, SERPINE3, SERPINF1, SERPINF2, SERPING1, SERPINH1, SERPINI1, and SERPINI2.
29. The preparation according to claim 25 , wherein more than 80% of the glycan structures of the recombinant human glycoprotein preparation comprises the structure A2G2S2 with the following pictorial representation:
30. The preparation according to claim 29 , wherein more than 80% of the glycan structures of the recombinant human glycoprotein preparation comprises the structure A2G2S2 with the following pictorial representation:
31. The preparation according to claim 29 , wherein the recombinant human glycoprotein is selected from the group consisting of
Plasma protease C1 inhibitor (C1Inh; SERPING1) glycosylated at one or more positions selected from Asn3, Asn47, Asn59, Asn216, Asn231, Asn250, and Asn330;
Antithrombin-III (ATIII; SERPINC1) glycosylated at one or more positions selected from Asn96, Asn135, Asn155 and Asn192; and
Human alpha-1-antitrypsin (AAT; SERPINA1) glycosylated at one or more, such as two or three of the positions Asn46, Asn83, and Asn247.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18/056,126 US20230272445A1 (en) | 2017-11-28 | 2022-11-16 | Glycosylation of proteins |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17204071 | 2017-11-28 | ||
| EP17204071.9 | 2017-11-28 | ||
| EP18182948 | 2018-07-11 | ||
| EP18182948.2 | 2018-07-11 | ||
| PCT/EP2018/081616 WO2019105770A1 (en) | 2017-11-28 | 2018-11-16 | Glycosylation of proteins |
| US202016767531A | 2020-05-27 | 2020-05-27 | |
| US18/056,126 US20230272445A1 (en) | 2017-11-28 | 2022-11-16 | Glycosylation of proteins |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2018/081616 Division WO2019105770A1 (en) | 2017-11-28 | 2018-11-16 | Glycosylation of proteins |
| US16/767,531 Division US11624080B2 (en) | 2017-11-28 | 2018-11-16 | Glycosylation of proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20230272445A1 true US20230272445A1 (en) | 2023-08-31 |
Family
ID=64332329
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/767,531 Active US11624080B2 (en) | 2017-11-28 | 2018-11-16 | Glycosylation of proteins |
| US18/056,126 Pending US20230272445A1 (en) | 2017-11-28 | 2022-11-16 | Glycosylation of proteins |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/767,531 Active US11624080B2 (en) | 2017-11-28 | 2018-11-16 | Glycosylation of proteins |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US11624080B2 (en) |
| EP (1) | EP3717640A1 (en) |
| WO (1) | WO2019105770A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023083859A1 (en) | 2021-11-09 | 2023-05-19 | Danmarks Tekniske Universitet | Variants of alpha-1-antitrypsin |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2167539A2 (en) | 2007-06-15 | 2010-03-31 | Charite-Universitätsmedizin Berlin | Methods for producing glycosylated human alpha-1 antitrypsin (a1at) in mammalian host cells |
| CN101883850B (en) | 2007-07-12 | 2014-11-12 | 桑格摩生物科学股份有限公司 | Methods and compositions for inactivating alpha-1,6 fucosyltransferase (FUT 8) gene expression |
| WO2009075883A2 (en) | 2007-12-12 | 2009-06-18 | University Of Georgia Research Foundation, Inc. | Glycoprotein cancer biomarker |
| AU2010244592B2 (en) | 2009-04-23 | 2016-05-19 | Janssen Vaccines & Prevention B.V. | Recombinant human alpha1-antitrypsin |
| CA2858825A1 (en) | 2011-12-19 | 2013-06-27 | Lfb Usa, Inc. | Recombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders |
| CN110438083A (en) | 2012-01-11 | 2019-11-12 | 西格马-奥尔德里奇有限责任公司 | The generation of recombinant protein with simple sugar-type |
| US11242551B2 (en) | 2013-12-20 | 2022-02-08 | Novartis Ag | Eukaryotic cells and methods for recombinantly expressing a product of interest |
| US10377990B2 (en) | 2014-03-04 | 2019-08-13 | Sigma-Aldrich Co. Llc | Viral resistant cells and uses thereof |
| EP3230438A2 (en) | 2014-12-12 | 2017-10-18 | University of Copenhagen | N-glycosylation |
| US10889845B2 (en) * | 2015-07-16 | 2021-01-12 | University Of Copenhagen | Production of N-glycoproteins for enzyme assisted glycomodification |
| WO2020047282A1 (en) | 2018-08-29 | 2020-03-05 | University Of Copenhagen | Lysosomal enzymes modified by cell based glycoengineering |
-
2018
- 2018-11-16 WO PCT/EP2018/081616 patent/WO2019105770A1/en unknown
- 2018-11-16 US US16/767,531 patent/US11624080B2/en active Active
- 2018-11-16 EP EP18804316.0A patent/EP3717640A1/en active Pending
-
2022
- 2022-11-16 US US18/056,126 patent/US20230272445A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210262000A1 (en) | 2021-08-26 |
| EP3717640A1 (en) | 2020-10-07 |
| WO2019105770A1 (en) | 2019-06-06 |
| US11624080B2 (en) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amann et al. | Glyco-engineered CHO cell lines producing alpha-1-antitrypsin and C1 esterase inhibitor with fully humanized N-glycosylation profiles | |
| US9512457B2 (en) | Serum-free stable transfection and production of recombinant human proteins in human cell lines | |
| EP1283265B1 (en) | Process for producing protein with reduction of mannose phosphate in the sugar chain and glycoprotein produced thereby | |
| Brondyk | Selecting an appropriate method for expressing a recombinant protein | |
| US20230272445A1 (en) | Glycosylation of proteins | |
| Jeong et al. | Enhanced sialylation of recombinant erythropoietin in CHO cells by human glycosyltransferase expression | |
| JP2007167062A (en) | High-efficiency secretory signal peptide and protein expression system using the peptide | |
| Ross et al. | Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER. C6 cells | |
| Kovnir et al. | A highly productive CHO cell line secreting human blood clotting factor IX | |
| JP2014532406A (en) | Engineered lower eukaryotic host strains for recombinant protein expression | |
| Lalonde et al. | Production of α2, 6-sialylated and non-fucosylated recombinant alpha-1-antitrypsin in CHO cells | |
| Koyuturk et al. | High‐level production of wild‐type and oxidation‐resistant recombinant alpha‐1‐antitrypsin in glycoengineered CHO cells | |
| Luley-Goedl et al. | Combining expression and process engineering for high-quality production of human sialyltransferase in Pichia pastoris | |
| EP1718752B1 (en) | A novel hansenula polymorpha gene coding for alpha 1,6-mannosyltransferase and process for the production of recombinant glycoproteins with hansenula polymorpha mutant strain deficient in the same | |
| US6933136B2 (en) | Method for making recombinant proteins | |
| US20210292783A1 (en) | Cho cell line, construction thereof and recombinant protein expression system using cho cell line | |
| US8003349B2 (en) | YLMPO1 gene derived from yarrowia lipolytica and a process for preparing a glycoprotein not being mannosylphosphorylated by using a mutated yarrowia lipolytica in which YLMPO1 gene is disrupted | |
| US9587245B2 (en) | N-glycosylation in transformed Phaeodactylum tricornutum | |
| WO2004027072A2 (en) | Method for making recombinant proteins | |
| WO2013019625A2 (en) | Methods of using a bacterial glcnac-6-p 2'-epimerase to promote sialylation of glycoconjugates | |
| KR101119079B1 (en) | Method for producing human coagulation factor VIII | |
| WO2020081328A1 (en) | Complement component 1s (c1s) deficient cells for production of vaccines and biopharmaceutical proteins | |
| Zettlmeissl et al. | Mammalian cell expression and characterization of recombinant human antithrombin III |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: DANMARKS TEKNISKE UNIVERSITET, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VOLDBORG, BJOERN GUNNAR;KOL, STEFAN;HANSEN, ANDERS HOLMGAARD;AND OTHERS;REEL/FRAME:061980/0889 Effective date: 20181123 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |